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ABSTRACT 
 
Paediatric Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS) remain a significant health care challenge in South Africa.  Oral 
health and coagulation are only two of the many problems experienced by HIV 
positive paediatric patients. 
 
This research report began with an observation that known HIV positive paediatric 
patients bled more than known HIV negative paediatric patients or those with 
unknown HIV status while undergoing dental extractions at Charlotte Maxeke 
Johannesburg Academic Hospital.  The observation prompted a prospective, 
contextual, descriptive study looking at the coagulation profile (platelet count and 
thromboelastogram (TEG) profile (reaction time (r-time), clot formation time (K-
time), alpha angle (α-angle) and maximum amplitude (MA)), CD4 counts and 
percentages and observed clinical bleeding in HIV negative, HIV positive not on 
antiretroviral treatment (ARVs) and HIV positive on ARVs paediatric patients 
presenting for dental extraction. 
 
Over a two year period 47 HIV negative, 12 HIV positive not on ARVs and 17 HIV 
positive on ARVs paediatric patients were enrolled in the study using a 
consecutive, convenience sampling method. Each paediatric patient was given a 
standard inhalational general anaesthetic using sevoflurane and during 
intravenous cannulation the researcher drew blood from each child for analysis.  A 
senior dentist from the Department of Paediatric Dentistry assessed bleeding in all 
cases.  
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The data obtained for each of the three study groups was compared using a one-
way analysis of variance followed by pair wise comparison using the Bonferroni 
adjustment to address multiplicity.  To deal with the big standard deviations and 
skewed data a one-way analysis of variance for ranks tested for differences 
between the groups.  No statistically significant differences were found when 
comparing the groups for platelet count (p = 0.2087), TEG r-time (p = 0.4738), 
TEG K-time (p = 0.6967), TEG α-angle (p = 0.7948) or TEG MA (p = 0.2982).  
There was a statistically significant difference between the HIV negative and HIV 
positive not on ARVs groups (p = 0.000 and 0.004) and HIV positive on ARVs and 
HIV positive not on ARVs groups (p = 0.000 and 0.001) when comparing CD4 
count and percentage.   
 
Patient groups were compared with respect to bleeding complications using the 
Fisher’s exact test.  There was no statistically significant difference in observed 
bleeding between the three groups of paediatric patients.  The entire HIV positive 
group was then compared for bleeding, and using the Welch t-test, adjusting for 
unequal variances it was found that there was statistically, significantly more 
bleeding in the HIV positive children with lower CD4 counts regardless of 
treatment with ARVs (p = 0.0129).  These results were also confirmed using the 
Wilcoxon rank-sum test (p = 0.0335).   
 
Although this study showed statistically significant bleeding in HIV positive 
paediatric patients with lower CD4 counts, the tests of coagulation used in the 
study were unable to define the underlying pathogenesis.  Further research into 
coagulation in HIV positive paediatric patients is needed. 
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CHAPTER 1: OVERVIEW OF THE STUDY 
 
This chapter will introduce the study.  This will be done by way of a background 
description followed by the setting out of the problem statement, aims and 
objectives of the study.  Definitions relevant to the study will then be defined.  A 
description of the location, ethical considerations, methodology, significance, 
validity and reliability of the study and potential limitations of the study will follow 
this.  An outline of the research report will then be given. 
 
1.1 Introduction 
It is estimated that more than 50 million people in the world have become infected 
with Human Immunodeficiency Virus (HIV) and that 36 million of these infected 
people are living in sub-Saharan Africa (1).  The Actuarial Society of South Africa 
estimates that 5,6 million South Africans are HIV infected, constituting 
approximately 15% of our population (2, 3).  Almost 30% of new infections have 
been amongst the young adult female population who spread HIV during 
pregnancy, parturition and breastfeeding to their children.  Consequently the 
epidemic in children is seen to parallel that of reproductive women (1).  In 2005 2,3 
million children worldwide were estimated to be HIV positive, however, there is no 
data to estimate the numbers in South Africa (4).  It is estimated that 20-25% of 
patients infected with HIV will need to undergo surgery at some time during their 
illness; this includes children (1, 4).    
 
Dental caries in children is an important primary health care issue.  It is estimated 
that 40% of five-year-olds in the United Kingdom have had caries (5).  In South 
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Africa, the 1999/2002 South African National Children’s Oral Health Survey 
published a dental caries prevalence of 51% in four-to-five-year-olds (6).  The 
incidence in HIV positive children may be higher as a result of 
immunosuppression.  These children are also at risk for complications of caries, 
namely periodontal disease and systemic infection (7). 
 
HIV can affect any of the human organ systems, including the haematological 
system. These effects on the haematological system include anaemia, 
leucopoenia, lymphoma, thrombocytopenia, bone marrow suppression, 
hypercoagulability, and Acquired Immune Deficiency Syndrome (AIDS)-related 
lymphoma (1, 4).  These effects are as a result of infection by the virus itself, 
antiretroviral drugs (ARVs), impaired nutrition and bone marrow infiltration by 
neoplasia or opportunistic infection (1).  HIV is known to affect the coagulation 
system. 
 
There are numerous tests currently in use for establishing the integrity of the 
coagulation system.  One of these tests is the thromboelastogram (TEG).  The 
TEG reports an amplitude measurement of the examination of whole blood clot 
strength over time (8).  There is currently no literature exploring the effects of HIV 
on the TEG in either the adult or the paediatric population groups.  
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1.2 Problem statement 
It was observed clinically that children known to be HIV positive bled more than 
those with unknown or known negative status when undergoing dental extractions 
at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).  At the time of 
this research project there was no research determining whether these HIV 
positive children had abnormal coagulation profiles as assessed by TEG or 
platelet count and whether abnormalities in these parameters were the reason for 
the observed increase in bleeding. 
 
1.3 Aims of the study 
This study was conducted in three parts: 
 
Part 1  
The aim of this part of the study was to determine if there was a difference in the 
coagulation profile of HIV positive paediatric patients (those on ARVs and those 
not on ARVs) and HIV negative paediatric patients undergoing dental extractions 
at CMJAH. 
 
Part 2 
The aim of this part of the study was to compare the CD4 counts and percentages 
of HIV positive paediatric patients on ARVs and those not on ARVs with that of the 
HIV negative paediatrics patients undergoing dental extractions at CMJAH. 
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Part 3  
The aim of this part of the study was to compare observed bleeding of the HIV 
positive paediatric patients (on ARVs and not on ARVs) with that of the HIV 
negative paediatric patients undergoing dental extractions at CMJAH. 
 
1.4 Objectives of the study 
The aims of the study were justified by the following objectives. 
 
Part 1 
• To describe the coagulation profile of HIV positive (on ARVs and not on 
ARVs) and HIV negative paediatric patients undergoing dental extractions. 
• To compare the coagulation profiles of these patients. 
 
Part 2 
• To determine the CD4 counts and percentages of HIV positive (on ARVs 
and not on ARVs) and negative paediatric patients undergoing dental 
extractions. 
• To compare the CD4 counts and percentages of the three groups. 
 
Part 3 
• To assess the observed bleeding in the HIV positive (on ARVs and not on 
ARVs) and the HIV negative groups of paediatric patients undergoing 
dental extractions. 
• To compare the observed bleeding between the groups. 
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1.5 Research assumptions  
The following definitions were used in this study. 
 
Paediatric patient: for the scope of this study a paediatric patient was a patient 
aged between one and thirteen years presenting for dental extraction. 
 
Bleeders: study patients observed to have excessive bleeding during dental 
extraction. 
 
Non-bleeders: study patients observed to have a normal amount of bleeding 
during dental extraction. 
 
Thrombocytopenia: a platelet count of less than 150 x 109/l (9, 10).  
 
Clinically relevant bleeding for the scope of this study:  
• loss of more than 10% of blood volume 
• haemodynamic instability as a result of blood loss 
• the need for admission as a result of blood loss 
• the need for blood transfusion following blood loss. 
 
Paediatric HIV infection: HIV infection in a child confirmed by the presence of the 
HIV RNA, DNA PCR, p24 antigen or HIV-specific antibodies detected in a serum 
sample of children over 18 months of age or at least six weeks after cessation of 
breastfeeding (4).   
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AIDS: the development of one or more AIDS defining conditions in the presence of 
HIV infection with or without a CD4 count of less than 200 x 106/l or less than 15% 
of the total lymphocyte count in the one to thirteen year age group. 
 
The CDC classification of immunological and clinical categories of HIV infection in 
children (table 1.1 and table 1.2) were used in this research (4). 
 
Table 1.1 CDC classification of immunological categories of HIV infection in 
children (4) 
Immunological Categories 
  
CD4 count (μl/%)   
  < 12 months 1-5 years 6-12 years 
No evidence of suppression >1500/>25 >1000/>25 >500/>25 
Evidence of moderate 
suppression 750-1499/15-24 500-999/15-24 200-499/15-24 
Evidence of severe 
suppression <750/<15 <500/<15 <200/<15 
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Table 1.2 CDC classification of clinical categories of HIV infection in children 
(4) 
Clinical 
categories Signs and symptoms 
  n No signs or symptoms or only one of category A event 
 
 A Mildly symptomatic 
 
At least 2 of: lymphadenopathy, hepatomegaly, splenomegaly, parotitis, rash, ear, 
nose and throat infections 
 
 B Moderately symptomatic 
Single episode of severe bacterial infections 
Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex 
Anaemia, neutropenia, thrombocytopenia 
Cardiomyopathy, nephropathy, hepatitis, diarrhoea 
Candidiasis, severe Varicella/zoster or Herpes simplex virus infections 
 C Severely symptomatic 
Two serious bacterial infections 
Encephalopathy: acquired microcephaly, cognitive delay, abnormal neurology 
Wasting syndrome: severe failure to thrive or downward crossing two weight centiles 
Opportunistic infections: Pneumocystis jirovecii, Cytomegalovirus, Toxoplasmosis, 
disseminated fungal infections  
Disseminated mycobacterial disease 
 
Malignancy: Kaposi's sarcoma, lymphoma 
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1.6 Location of the study 
The study took place at CMJAH, Gauteng Province, South Africa.  CMJAH is an 
academic hospital associated with the University of the Witwatersrand.  It is a 
tertiary hospital acting as a referral hospital for a number of smaller regional 
hospitals. 
 
1.7 Ethical considerations 
Ethical approval for the study was sought from the Human Research Ethics 
Committee (HREC) (Appendix 1) of the University of the Witwatersrand, 
Johannesburg, Gauteng Province, South Africa. 
 
Approval for the study was verbally obtained from the authorities of CMJAH. 
 
After discussion and explanation of the study and giving of an information packet, 
written informed consent was obtained from the parent or legal guardian of each 
paediatric patient prior to admission into the study.  Assent was sought from the 
paediatric patients who were six years or older.  Appendices 2 to 8. 
 
Patients and their guardians who had an HIV test for the purposes of the study 
received pre- and post-test counselling. 
 
1.8 Research methodology 
 
1.8.1 Research design 
A prospective, contextual, descriptive research design was followed in this study. 
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1.8.2 Study population and sample 
 
Study population 
The study population was all paediatric patients presenting for dental extraction at 
CMJAH. 
 
Study sample 
Sample statement 
In consultation with a biostatistician a sample size of 16 paediatric patients in each 
group was used.  This sample had 90% power to detect a difference in means of 
4.0 (one standard deviation) assuming that the common deviation is 3.3 
(reference) using a two group t-test with a 0.05 two-sided significance level (11, 
12, 13). 
 
Sampling method 
A consecutive convenience sampling method was used in this study. 
 
The convenience sampling method was chosen because of the time constraints 
and the scope of the research.  The most readily accessible paediatric patients 
presenting for dental extraction were included.  It is acknowledged that a 
convenience sample cannot fully represent the study population (14). 
 
The study further used a consecutive sampling method where every paediatric 
patient who presented for dental extraction was invited to take part in the study.  
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Consecutive sampling is the most reliable form of convenience sampling as 
research bias is limited (14). 
 
Inclusion criteria 
The following inclusion criteria were used for the study: 
• known HIV positive paediatric patients on ARVs 
• known HIV positive paediatric patients not on ARVs 
• HIV negative paediatric patients. 
 
Exclusion criteria 
The following exclusion criteria were used for the study:  
• refusal to give consent 
• HIV positive or negative paediatric patients known to have a coagulation 
abnormality. 
 
1.9 Significance of the study 
The Declaration of Helsinki states that, “the purpose of biomedical research 
involving human subjects must be to improve diagnostic, therapeutic and 
prophylactic procedures and the understanding of the aetiology and pathogenesis 
of disease” (15). 
 
This study increased the understanding of coagulation in HIV positive children.  
The identification of patients who are at increased risk of bleeding during dental 
extraction and surgery is desirable, as this will allow for preparation and better 
care of such patients. 
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The study may promote further study into bleeding in HIV positive children. 
 
1.10 Validity and reliability of the study 
The validity and reliability of the study were increased by the following measures. 
 
In order to ensure that standard practices were adhered to and reliable results 
were obtained, one anaesthesiology technician trained in TEG analysis performed 
all the TEG analyses for this study.  A single TEG machine (TEG®) was used to 
limit variance that might occur between machines.  The machine was calibrated to 
manufacturer standards on each day that TEG analysis was performed to ensure 
accurate results were obtained. 
 
Blood specimens drawn for HIV testing, platelet count and CD4 count and 
percentage were sent to the National Health Laboratory Services (NHLS) 
laboratory at CMJAH.  In this accredited laboratory Good Laboratory Research 
Practices are adhered to ensuring reliable results from these tests. 
 
The researcher personally collected all data prior to analysis (Appendix 9).  This 
ensured that data was collected in a standard manner from reliable sources. 
 
Assessment of an increase in observed bleeding was subjective.  To limit the 
subjectivity of this observation only one senior member of the Department of 
Paediatric Dentistry assessed bleeding in all the paediatric patients who had 
dental extractions. 
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1.11 Potential limitations 
The study was done contextually at CMJAH.  This context may not allow for 
generalisation of the results of the study, however, it was an important study to be 
done in that context as it addressed an observed problem. 
 
The limited number of study subjects could affect the ability to generalise the study 
results.  It may, however, provide a baseline to direct further research. 
 
The assessment of clinical bleeding was subjective.  In order to standardise this 
observation bleeding was assessed by one senior dentist from the Department of 
Paediatric Dentistry at CMJAH. 
 
1.12 Outline of the research report 
The research report will be presented as follows. 
 
Chapter 1 – Overview of the study. 
 
Chapter 2 – Literature review of relevant aspects. 
  
Chapter 3 – Discussion of the research methodology. 
  
Chapter 4 – Presentation of the research results. 
  
Chapter 5 – Discussion of the research results. 
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Chapter 6 – Conclusions and recommendations.  
 
1.13 Conclusion 
This chapter has introduced the study.  The problem statement was stated 
followed by the aims and objectives of the study.  Definitions relevant to the study 
were defined.  The methodology to be used was briefly described, as were the 
location, ethical considerations, validity and reliability, potential limitations and 
significance of the study.  Finally an outline of what will be covered in each chapter 
of the report was given. 
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter will be a discussion of current literature relevant to the study.  It will 
be discussed under the following headings:  Coagulation and tests of coagulation, 
and Human Immunodeficiency Virus. 
 
2.1 Coagulation and tests of coagulation 
 
2.1.1 Coagulation and fibrinolysis 
When there is a balance between bleeding and thrombosis, haemostasis is 
normal.  Coagulation relies on the interaction between endothelium, platelets, and 
coagulation factors (16).  With injury to the endothelium tissue factor is exposed 
and interacts with factor VII.  Von Willebrand factor exposes glycoprotein Ib for 
platelet binding, and stimulates exposure of glycoprotein IIbIIIa binding sites, 
resulting in further attachment of von Willebrand factor and fibrinogen (17, 18). 
 
Dense granules from the platelets release ADP (resulting in platelet aggregation 
and disintegration), serotonin and thromboxane A2 (causing vasoconstriction and 
calcium release).  Alpha granules from the platelets release fibrinogen, 
thrombospondin, fibronectin, factor V and factor VIII.  Phospholipid 
phosphatidylserine is exposed on the platelet surface and serves as a base for 
initiation of clot formation (17). 
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The interaction of tissue factor, calcium and factor VII on the platelet surface 
rapidly initiates coagulation.  This complex activates factors IX and X.  Factor XIa 
enhances factor X production with factor VIIIa acting as a co-enzyme (18, 19). 
 
Factor Xa then converts prothrombin to thrombin with the facilitation of co-enzyme 
Va.  Thrombin then cleaves fibrinogen, which forms fibrin, this then polymerises to 
form a fibrin clot.  Factor XIII stabilises the clot by forming covalent bonds between 
the fibrin molecules (18, 19). This process is illustrated in figure 2.1. 
 
Thrombin formation is enhanced by its own activation of co-enzymes V and VIII, 
activation of factor XI, and by encouraging platelet aggregation and disintegration 
(19). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The coagulation cascade (19) 
Tissue injury 
Tissue factor 
Factor VII 
Calcium 
 
   XI          XIa   IX        IXa                                                 X        Xa    
Phospholipid 
Factor VIII 
Calcium 
  Thrombin            Prothrombin 
     Cross-linked fibrin             Fibrin            Fibrinogen 
 XIII 
Phospholipid 
Factor V 
Calcium 
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Inhibitors regulate the process of coagulation.  Prostaglandin I2 prevents platelet 
activation and causes vasodilatation.  Antithrombin and heparan sulphate 
inactivate thrombin, factor IXa, factor Xa and factor XIa.  Protein C, activated by 
the thrombin-thrombomodulin complex, inactivates factor Va and factor VIIIa in the 
presence of cofactor Protein S.  Extrinsic Pathway Inhibitor binds factor Xa and 
tissue factor, inhibiting both.  Finally, damaged endothelial cells release tissue 
plasminogen activator and urokinase, which stimulate the fibrinolytic pathway.  
Fibrinolysis is activated by tissue injury (18, 19, 20).   
 
Tissue plasminogen activator and urokinase cleave plasmin from plasminogen and 
fibrin bonds.  Plasmin degrades factor Va, factor VIIIa and glycoprotein Ib, and 
fibrin into D-dimers and fibrin degradation products.  The negatively charged, 
exposed subendothelium activates factor XII, which then releases kallikrein from 
prekallikrein (19).  Fibrinolysis is illustrated in figure 2.2. 
 
Kallikrein activates plasmin from plasminogen and releases bradykinin from 
kininogen.  This activates a pro-inflammatory process (19). 
 
Plasminogen activator inhibitor 1, alpha 2 antiplasmin and alpha 2 macroglobulin 
are inhibitors of the fibrinolytic pathway (19). 
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Figure 2.2: The process of fibrinolysis (19)  
 
2.1.2 Traditional tests of coagulation and platelet function 
The partial thromboplastin time (aPTT) and prothrombin time (PT) are tests used 
for coagulation screening.  Both use exogenous reagents to measure the clotting 
time in plasma and do not reflect any interaction between cells, endothelium and 
fibrin.  The tests are affected by high haematocrit, difficult venepuncture, and 
incorrect concentration with citrate.  Watson and Greaves (21) maintain that these 
tests are insufficiently sensitive and specific to be used as principal screening tests 
for coagulation, and are not useful for platelet function screening.  The aPTT is 
useful for the diagnosis of disseminated intravascular coagulation and for the 
quantitative assessment of factor VIII.  The aPTT records only the beginning of the 
overall clotting process, leaving at least 95% unrecorded (22). 
Tissue injury 
 
Tissue Injury 
                      XII        XIIa                                                 
   Plasminogen                                                   Plasmin 
                                                               Fibrin          FDP 
           D-dimers 
                                               Va, VIIIa, GPIb           Inactivated 
   
   
    
   
   Prekallikrein          Kallikrein Release of tPA and urokinase 
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The bleeding time was described by Milian (in 23) in 1901 and by Duke (in 23) in 
1910.  It involves touching a piece of filter paper to the edge of a wound (of 
standard length, depth and direction on the forearm with a sphygmomanometer 
cuff inflated to 40 mmHg on that arm) at set time intervals and measuring the time 
taken for bleeding to stop.  It is affected by emotion, temperature and exercise, 
and is poorly reproducible.  The bleeding time is no longer thought to be a 
reasonable preoperative screening test of haemostatic function (21, 23).   
 
Kratzer and Born (in 23) designed a platelet function analyser in 1985, which 
stimulates platelet adhesion and aggregation under high shear forces.  This was 
followed by the Platelet Function Analyser-100 in 1995, which occludes an 
aperture by contact between platelets and agonists, thus stopping blood flow and 
giving a closure time.  These tests were found not to be sensitive or specific 
enough to be used as screening tests for platelet disorders.  They are, however, 
more sensitive than the bleeding time (21, 22, 23).  The Platelet Function 
Analyser-100 is useful for the diagnosis of von Willebrand’s Disease (22). 
 
Platelet aggregometry was developed in 1962.  Adhesion, aggregation, and 
platelet secretion of components of coagulation are evaluated.  This is a useful 
test of platelet function defects and it assesses primary haemostasis.  Qualitative 
defects in platelet function can further be analysed by measuring various 
parameters including intraplatelet adenine nucleotides (21, 23). 
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Flow cytometry of platelet surface glycoproteins evaluates circulating platelet 
activation and reactivity, diagnoses platelet disorders, and monitors efficacy 
antiplatelet agents (23). 
 
Recently there has been a questioning of whether these tests are useful in the 
acute perioperative period.  There is a time delay in receiving test results, they are 
performed in plasma and not in whole blood, and give limited information on 
platelet function (24).  TEG monitoring is rapid, performed as a point of care test at 
body temperature and gives information about platelet function.  It is, therefore, an 
assessor of the global coagulation mechanism (21, 24). 
 
Watson and Greaves (21) conclude that the cornerstone of the assessment for 
bleeding risk is still a thorough clinical history and examination of the patient prior 
to surgical procedures.  
 
2.1.3 Thromboelastography 
Hartert (in 23) first described thromboelastography in 1948.  It was used as a 
method to describe global haemostatic function from a single blood sample.  The 
TEG is the trace produced from the measurement of viscoelastic changes 
associated with fibrin polymerisation (25).  The clotting process, starting with fibrin 
formation and continuing to clot retraction and fibrinolysis is measured at the 
bedside (17, 24).  Unlike traditional tests of clotting, the TEG is not based on static 
isolated endpoints.  It measures the interaction of platelets and the clotting 
cascade. 
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TEG is a registered trademark of the assay performed by the Haemoscope 
Corporation’s instrument and ROTEM is the registered trademark of Pentapharm 
GmbH (24).  Both of these instruments produce a graphical representation of the 
measurement of visicoelastic changes during clot formation. 
 
The TEG has been used for the following purposes. 
• Assessment of haemostasis. 
• There have been reports of TEG abnormalities in thrombocytopenic 
pre-eclamptic women.  Clot formation time (K-time) and maximum 
amplitude (MA) were reduced as the platelet count deceased (25, 26, 
27). 
• TEG has been found to reflect the clinical state of haemostasis in 
neonates better than conventional tests of coagulation (25). 
• The TEG has been used for risk stratification of children with 
snakebite, by identifying clotting abnormalities (28). 
• Monitoring of blood component therapy in surgery for adults and children.  It 
has been used in the following types of surgery:  
• liver transplantation 
• cardiac surgery 
• trauma patients. 
• The TEG has been seen to reduce the intraoperative use of fresh frozen         
plasma, blood and platelets.  TEG analysis can also reduce the 
postoperative blood loss and need for relook surgery by determining 
whether bleeding is the result of a coagulation defect, or of inadequate 
surgical haemostasis (24, 25, 29, 30, 31, 32).   
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• Pharmaceutical monitoring. 
• Patients on treatment with low molecular weight heparins or heparinoids 
and direct thrombin inhibitors can be monitored by means of the TEG 
(24, 25). 
• Heaney et al. (33) showed that perioperative diclofenac does not 
adversely affect clot strength in children undergoing tonsillectomy. 
• Hypercoagulability screening and assessment of thrombotic risk. 
• The TEG has been used to assess and manage postpartum 
coagulopathy that may exist for 24 hours post-delivery (25, 26, 27, 34). 
• The TEG has demonstrated hypercoagulability in paediatric patients 
with Sickle cell disease (35). 
• The TEG has demonstrated the existence of a hypercoagulable state in 
adult and paediatric neurosurgical patients (36). 
• Monitoring of recombinant factor VIIa and activated prothrombin complex 
treatment in haemophilia (25). The TEG has also been used to assess 
coagulation in children with haemophilia (37). 
 
The TEG is a bedside test that, within 30 minutes, can deliver a graphical 
representation of platelet function, coagulation proteases and inhibitors, and the 
fibrinolytic system (25).  The TEG measures the interaction between platelets, 
clotting factors and fibrinogen as opposed to other coagulation tests which assess 
isolated portions of the coagulation cascade (34).  The TEG is helpful in identifying 
a cause for bleeding and thus is a guide for coagulation therapy.  The TEG better 
reflects haemostatic potential than traditional tests of coagulation (24, 38).  In their 
study of 12 normal adult subjects Valeri and Ragno (39) concluded that the TEG 
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could not be used to predict the bleeding time as the bleeding time did not 
correlate with the TEG tracing.  
 
The TEG is a graphical representation of thrombosis and lysis of a blood clot.  
When a TEG® is used 360 µℓ of blood is placed in an oscillating cup at 37°C. The 
cup oscillates through an angle of 4°45’ every 10 s econds.  A pin with a torsion 
wire is suspended in the cup; this is the detection device.  As a clot forms a 
tracing, as seen in figure 2.3, is generated.  Reaction time (r-time) is the time 
taken for initial clot formation. K-time is the coagulation time from 2-20 mm of clot 
size.  The alpha angle (α-angle) is the slope of the TEG from the r-time to the K-
time.  MA is the maximum amplitude of the TEG and is the reflection of the 
absolute strength of the clot.  A60 is the amplitude after 60 minutes and is a 
measure of clot lysis (17, 25, 40). 
 
Figure 2.3: The thromboelastogram tracing (40) 
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The r-time is influenced by the intrinsic activity of clotting factors, fibrinogen, and 
platelets.  In liver transplant surgery a shortened r-time may indicate the need for 
fresh frozen plasma infusion.  MA is deceased by platelet abnormalities or 
deficiencies.  The α-angle is a measure of the speed at which clot forms and is 
decreased by hypofibrinogenemia and thrombocytopenia; in liver transplantation 
this indicates a need for cryoprecipitate infusion (17, 24, 25, 40).  A short r-time 
may be present with hypercoagulability syndromes, the K-time influenced by 
activity of clotting factors, fibrinogen and platelets, a decreased α-angle by 
thrombocytopenia, and MA altered by platelet abnormalities (40).      
 
The ROTEM® differs from the TEG® as it uses an optical detection device system, 
not a torsion wire, initiates movement from the pin, not the cup, and is equipped 
with an electronic pipette (24). 
 
The nomenclature and reference ranges for the TEG® and ROTEM® are different 
and are set out in table 2.1.  The reliability of measurements from these two 
methods is within acceptable ranges (24).  In their “head-to-head” comparison of 
the TEG® and ROTEM® systems Jackson et al. (41) found that the TEG® had the 
best compromise between user-friendliness, cost and usefulness in their setting.  
Normal values between centres are not standardised, however, if analysis within a 
centre is performed in a standardised manner, results are valid (25). 
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Table 2.1: Comparative values: TEG® and ROTEM® (25) 
  
TEG® ROTEM® 
Clotting time (min) (time to 2 
mm amplitude) r CT 
Clot formation time (min) (time 
from 2-20 
mm amplitude) 
K CFT 
Maximum clot strength MA MCF 
Alpha angle α (slope between r and K) α (slope of tangent at 2 
mm amplitude) 
Maximum angle ˗ CFR 
Time to maximum strength TMA MCF-t 
Amplitude at set time A (A30, A60) A (A5, A10…) 
Clot elasticity G MCE 
Maximum lysis ˗ ML 
Lysis at fixed time CL30, CL60 LY30, LY45, LY60 
Time to lysis TTL (2 
mm drop from MA) CLT (10% of MCF) 
Maximum lysis ˗ CLR (maximum tangent post-MCF) 
Measurement period ˗ RT 
 
 
The normal reference values for TEG in adults are as follows: 
 r-time   4-8 minutes (whole blood), 3-8 minutes (citrated/kaolin) 
 K-time 1-4 minutes (whole blood), 1-3 minutes (citrated/kaolin) 
 α-angle 47°-74° (whole blood), 55°-78°(citrated/kaol in) 
 MA  55-73 mm (whole blood), 51-69 mm (citrated/kaolin) (24)  
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Fresh whole blood has traditionally been used for the TEG.  This fresh blood must 
be placed in the TEG within 4-6 minutes of venesection for analysis (31, 42).  
Celite can be added as an adjunct to accelerate the clotting process; it consists of 
inert silica particles that act as a surface to activate factor XII and platelets (34, 
36).  Normal ranges of parameters of the TEG have been established for fresh 
whole blood.  Currently validation studies are being carried out on the use of 
citrated blood for the TEG.  Citrate causes incomplete inhibition of coagulation 
cascade activation (25).  It is suggested that citrated samples must rest for at least 
30 minutes before analysis in the TEG begins in order for standardisation of 
results (24, 25).  Citrated samples can be stored at room temperature or at 4ºC 
and must be recalcified before TEG analysis (42).  Bowbrick et al. (42) showed no 
significant difference in TEG results of citrated whole blood kept at room 
temperature for 30 minutes or at 4ºC for 45 to 150 minutes when compared to 
fresh whole blood samples. 
 
A temperature of 4˚C can cause platelet damage and induce coagulation.  It is 
possible that the platelets do not play a significant role in the TEG profile unless 
there is a thrombocytopenia of <66 x 109/l (16, 42).  Orlikowski et al. (27) found 
that the TEG performed adequately as a screening test for coagulation when 
compared with traditional screening tests (platelet count, PT, aPTT and fibrinogen) 
and that platelet counts of more than 54 x 109/l were associated with adequate clot 
formation on the TEG. 
 
Limitations of the TEG exist.  The TEG cannot identify specific factors responsible 
for coagulopathy, results are not standardised between institutions and it has not 
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been validated (24, 31).  TEG tests are performed under static conditions in a 
cuvette, thus there is no flow as in a vessel, and no interaction with endothelial 
cells (24).  This necessitates careful interpretation of the TEG results.  To ensure 
accuracy of the TEG there must be strict procedures for collection and handling of 
blood samples by trained personnel (24, 32).   
 
Age and gender influence TEG tracings in adults (24).  Miller et al. (43) showed 
that platelet counts and fibrinogen levels correlate with TEG tracings in adults and 
children over the age of 12 months.  The aged tend toward a hypercoagulable 
state, as do women when compared to men (44).    
 
2.1.4 HIV and TEG 
There is currently no research on the effects of the haematological changes of HIV 
on the TEG. 
 
2.1.5 Paediatric patients, coagulation and testing of coagulation 
There are currently no publications on paediatric HIV infection and the TEG.  The 
small amount of blood needed for TEG analysis may be beneficial for children 
(31).  Normal values for TEG analysis using whole blood and analysis within six 
minutes of venesection in children have been established and are shown in table 
2.2.  Rajwal et al. (31) recommend that if citrated whole blood is to be used, 
normal ranges need to be established. 
 
There is a functional difference in fibrinogen between children and adults, and a 
decrease in contact and vitamin K dependent clotting factors, and coagulation 
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inhibitors, especially in children less than 12 months of age when compared to 
adults.  Children less than one year of age develop clot faster than adults (43).  
After 12 months fibrinogen matures and levels increase to adult levels, and 
interaction with platelets corresponds with that of adults, although maturation is not 
yet complete.  The TEG (celite-activated) and heparinase-modified TEG tracings 
of healthy children and adult groups are comparable (31, 38, 43, 44, 45, 46, 47, 
48).  Age-specific reference ranges for kaolin-activated TEG tracings have recently 
been established (49).  In children less than one year old there is functional 
maturity of the coagulation system seen by TEG monitoring, despite the lower 
factor levels.  In children less than three months old the r-time is significantly 
shorter (45, 46, 50).    
 
Oswald et al. (50) showed that there were no gender-related differences in 
ROTEM® parameters in all children younger than sixteen years in their study. 
 
Current literature confirms that the inhalational anaesthetic agent Sevoflurane has 
no effect on platelet function or number (50). 
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Table 2.2: TEG reference values for paediatric patients (49, 51)                                     
  
Celite-activated TEG 
(children 4-9 years)  
Citrated whole blood with 
calcium chloride (children 
6.5 ± 4.8 years)  
Adult 
r-time (mins) 9.6 ± 2.5 8.7 ± 2.6 11.1 ± 3.0 
K-time (mins) 2.8 ± 0.6 2.1 ± 0.7 2.7 ± 0.6 
α-angle 
(degrees) 72.9 ± 4.2 61.6 ± 7.1 70.7 ± 3.9 
MA (mm) 70.5 ± 3.3 59.6 ± 4.2 70.2 ± 3.7 
                                   
2.2 Human Immunodeficiency Virus  
 
2.2.1 HIV background 
HIV is a lentivirus and a member of the human retrovirus subtype (1).  Before 
1986, when an international committee termed it HIV, there were various 
confusing names for the virus that was causing AIDS (52).  
 
A theory of the origin of HIV is that a simian transmitted Simian Immunodeficiency 
Virus to humans in West Africa in 1931 (52, 53).  HIV was identified in 1983, under 
much controversy, by Montagnier’s research team in Paris and Gallo’s research 
team in the United States of America (52, 54).  The first cases of AIDS in the 
United States of America were described in June 1981 in adult, homosexual men 
and in 1982 in paediatric patients (4, 54, 55).  A disease called ‘Slim’ disease was 
seen in Uganda following the opening of trade routes for truckers in 1982; it was 
characterised by diarrhoea and a wasting syndrome (52).  AIDS-like symptoms 
were reported in both sexes in the Congo and Rwanda in 1984 (52). 
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HIV has a cytopathic action.  Characteristically a person infected with this virus 
has a long latency period, with persistent viraemia, before being diagnosed with 
AIDS.   If untreated 10% of patients will be diagnosed with AIDS within two to 
three years of infection, the remainder are diagnosed with AIDS within ten years of 
infection.  It is this silent period that allowed HIV to spread unnoticed during the 
1970’s and has resulted in the pandemic seen today (53).  By 1985 there were 
diagnostic kits available for the detection of HIV antibodies in infected persons 
(52).   
 
In the United States of America AIDS changed from an unmentionable disease in 
the early 1980’s to the leading cause of death in the young adult population by 
1994 (54).  The advent of antiretroviral drugs changed the mortality from HIV in the 
developed world.  The first agent to be licensed was zidovudine (AZT), a reverse 
transcriptase inhibitor, in 1987 (54).  Other drugs of the same class and then 
protease inhibitors followed this in 1995 (52, 54).  Most recently cell-entry 
inhibitors and integrase inhibitors have been licensed (52).  
 
HIV targets the immune system and selectively depletes the CD4 T helper cells.   
Infected persons are susceptible to mycobacterial, bacterial, viral and malignant 
diseases (1).   
 
2.2.2 HIV epidemiology 
It is estimated that more than 50 million people in the world have become infected 
with HIV (around 40 million are living with HIV) and that 36 million of these infected 
people are living in sub-Saharan Africa. This is 10% of the sub-Saharan 
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population.  This is a high percentage of the population and will result in a 
deepening of poverty, and diminish food and health care resources (1, 4, 56).  The 
burden on health care resources is large, with 50% of hospital beds in sub-
Saharan Africa being occupied by patients with HIV-related diseases (56).  The 
Actuarial Society of South Africa estimates that 5,6 million South Africans are HIV 
infected, that is at least 15% of our population (2, 3).  
 
Almost 30% of new infections have been amongst the young adult female 
population who spread HIV during pregnancy, parturition and breastfeeding to 
their children.  Consequently the epidemic in children is seen to parallel that of 
reproductive women.  Nearly 10% of childhood mortality in sub-Saharan Africa 
(2004) is HIV-related (1, 56).  In the developed world the incidence of vertical 
transmission has been reported to be as low as 1-2% with the use of antiretroviral 
agents and elective caesarean sections.  In developing countries where such 
interventions are not always possible the following interventions may be 
acceptable in trying to reduce the rate of vertical transmission of HIV, vitamin and 
nutritional supplementation, vaginal cleansing, passive immunisation, and 
prophylaxis for chorioamnionitis (57).  
 
Some children become infected by unsafe injections, sexual transmission, 
household contact, or by exposure to infected blood products (1, 57).  In 2005 2,3 
million children worldwide were estimated to be HIV positive and by 2006 this 
estimate had grown to more than three million (56).  Nearly 90% of HIV infected 
children live in sub-Saharan Africa (58).  
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Access to antiretroviral agents has significantly decreased the morbidity and 
mortality associated with HIV/AIDS especially in the developed world.  In the 
developing world, however, there are severe human and financial resource 
shortages thus increased morbidity and mortality as compared to developed 
countries.  The World Health Organisation (WHO) aimed to provide three million 
people in the developing world with ARVs by 2005 (56).  In a WHO report from 
2010 it was estimated that 23% of the children living with HIV in the developing 
world were receiving ARVs (59) 
 
It is estimated that 20-25% of patients infected with HIV will need to undergo 
surgery at some time during their illness; this includes children (1, 4).  If the CD4 
count is less 50 cells/µl at the time of surgery, it is suggested that the six month 
mortality is 13.3% and if less than 200 cells/µl, 0.8% (52). 
 
2.2.3 Effects of HIV on the haematological system, in particular, the platelets  
HIV affects almost every organ system in the human body.  This includes the 
cardiovascular system, respiratory system, haematological system, renal system, 
nervous system, and growth and nutrition in children (4).  The primary effects of 
HIV are on the haematological system (55). 
 
There is a broad range of haematological manifestations of HIV infection.  
Characteristically there is a decrease in CD4 T lymphocytes in all untreated 
patients.  This may be accompanied by anaemia (in 70% of patients), 
granulocytopenia (in 50-70% of patients), thrombocytopenia (in 10-40% of 
patients), and lymphopenia.  These changes may be as a result of increased 
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peripheral destruction of cells or decreased production of cells because of direct 
bone marrow suppression by HIV, opportunistic infection, tumour infiltration or 
from treatment therapies.  These therapies include antiretroviral, antimicrobial and 
antitumour agents (9, 55, 60, 61). 
 
HIV itself suppresses the bone marrow.  This is evidenced by an increase of 
cellular deficiencies with advancing disease.  However, isolated thrombocytopenia 
is often the presenting manifestation of HIV infection and is thus not considered a 
criterion for advancing disease and progression to AIDS (60). 
 
Infectious agents that infiltrate bone marrow and suppress cell production or cause 
reticuloendothelial dysfunction include: Mycobacterium avium intracellulare; 
Mycobacterium tuberculosis; Cytomegalovirus; Cryptococcus neoformans; and 
Histoplasma capsulatum (60). 
 
The metastatic diseases, which infiltrate the bone marrow and thus contribute to 
the haematological manifestations associated with HIV infection, include Kaposi 
sarcoma and lymphoma (60). 
 
Thrombocytopenia in AIDS has a complex, multifactorial aetiology, which includes 
the following:  there is often immune mediated destruction of platelets (usually 
occurring earlier in the disease process) by circulating immunoglobulins, platelet 
bound IgG, complement or antibody complexes (there is cross-reaction between 
HIV gp120 and thrombocyte gp3a, and between HIV p24 antibodies and platelets) 
against platelet antigens.  These antibodies are due to a defect in regulation of 
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antibody production characterised by HIV infection.  B-cell regulation, activation 
and response are abnormal as a result of the HIV infection, or other viral infection 
(for example hepatitis B virus).  Other possible aetiologies for the 
thrombocytopenia include decreased and defective production in the bone marrow 
(which also shortens platelet life-span), a side effect of drugs taken, syndromes 
mimicking haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura, 
hypersplenism, disseminated intravascular coagulation, or an increase in the 
peripheral destruction and fragmentation of platelets (platelets are directly 
attacked by HIV through CD4 and CXCR4 receptors).  There might be a decrease 
in thrombopoietin production in hepatocytes in those HIV infected patients with 
liver disease (9, 55, 60, 62). 
 
Guidelines suggest that the treatment of thrombocytopenia only be instituted in 
those patients with very low platelet counts or those with severe bleeding.  
Treatment of thrombocytopenia with the standard approach of steroids, 
splenectomy, transfusion, and in the case of HIV antiretroviral agents, is 
controversial because of the immunosuppressive nature of these modalities.  This 
often complicates treatment of HIV infected persons with thrombocytopenia.  
Some thrombocytopenic seropositive patients have responded well to intravenous 
gamma globulins, anti-Rh(D), platelet infusion, vincristine, danazol, or interferon 
alpha 2a.  Treatment modalities for thrombocytopenia have been associated with 
accelerated disease progression, increased costs and transmission of infections 
(9, 60). 
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Thrombocytopenia is associated with rapid disease progression in the HIV infected 
person, which is a decrease in CD4 count and earlier diagnosis of AIDS.  
However, isolated thrombocytopenia may present at any stage of the disease (55).  
A 4% increase in mortality from bleeding has been observed in thrombocytopenic 
patients (9, 52).  Platelets also play a part in inflammatory and immunological host 
defences by secreting antimicrobial peptides and expressing cytokines.  Platelet 
internalisation of HIV has been suggested as a mechanism of viral clearance (61).  
In addition to immune-mediated thrombocytopenia, there are often antibodies to 
erythrocytes and granulocytes. 
 
HIV is known to affect the coagulation system.  Antiphospholipid antibodies and 
lupus-like anticoagulant of IgG type have been found in 20-70% of HIV positive 
people.  This antibody is associated with active opportunistic infection in patients 
and these patients are seen to have a prolonged activated partial thromboplastin 
time.  HIV-associated antiphospholipid antibodies do not have the same 
association with hypercoagulability that these antibodies do in HIV negative 
patients (60, 63). 
 
Coagulation abnormalities in HIV positive patients may be due to the above 
antibodies and anticardiolipin antibodies, thrombocytopenia or platelet function 
abnormalities.  The following bleeding abnormalities have been seen; prolonged 
bleeding time and abnormal platelet aggregation (55, 60).  As well as the 
predisposition to an increased bleeding tendency, there have also been reports of 
hypercoagulability in HIV positive people.  This is related to coexisting 
malignancies, autoimmune disease or as a result of drug therapy (1).  Saif and 
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Greenberg (64) found the following abnormalities that predispose to 
hypercoagulability: protein C and S deficiencies; heparin cofactor II deficiency; 
antithrombin III deficiency; abnormalities of fibrinolysis; lupus anticoagulant; 
antiphospholipid antibody syndrome; malignancy; myeloproliferative disorders; 
autoimmune diseases; stasis; altered lipid metabolism and lipodystrophy; 
antiretroviral drugs; thrombotic thrombocytopenia purpura; and infections (62, 64).  
Saber et al. (65) added dehydration from diarrhoea, immobility, intravenous drug 
abuse, and Cytomegalovirus endothelial procoagulant activity as possible 
mechanism for HIV/AIDS associated hypercoagulability.  Levine et al. (66) showed 
that advancing age as well as HIV disease, megestrol acetate or indinivir 
treatment, and progressive abnormalities of protein S and factor VIII leads to 
hypercoagulability. 
 
Vitamin B12 or cyanocobalamin deficiencies are found in 20% of patients with AIDS 
(60).  Vitamin B12 is necessary for erythropoiesis, DNA and myelin synthesis, and 
other metabolic processes.  A deficiency manifests, amongst other symptoms, with 
a megaloblastic anaemia.  If severe, vitamin B12 deficiency results in a 
pancytopenia (20, 40).    
 
2.2.4 Antiretroviral agents and coagulation 
ARV treatment has significantly modified the course of HIV disease.  There is an 
improvement in quality of life and survival of people infected with HIV.  The 
measurement of the CD4 count, and its increase (rapidly, at first and then more 
gradually) and normalisation (in the majority of cases), has generally been 
considered as a marker of successful therapy.  This increase in CD4 count usually 
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corresponds with a decrease in the viral load.  A patient’s prognosis will approach 
that of an HIV negative individual when the CD4 count remains consistently high; 
more than 500 cells/mm3 (67).   ARVs are, however, not without side effects. 
 
Long-term treatment with AZT is associated with bone marrow suppression and 
pancytopenia (1).  AZT is a nucleoside reverse transcriptase inhibitor, which 
inhibits viral replication by acting as a false substrate for reverse transcriptase and 
thus terminating the DNA chain (68).  AZT inhibition of DNA polymerases in bone 
marrow cells impairs haemopoietic cell production. Of patients on AZT, 34% will 
be anaemic, 16% will be neutropenic and 12% will have thrombocytopenia (usually 
with a 50% reduction in platelet count).  Platelets are usually the spared 
haemopoietic line.  Those patients with low CD4 counts prior to initiation of AZT 
and those with pre-existing cytopenias are more at risk from this side effect of 
AZT.  If paracetamol is used concomitantly there is a further increase in the 
incidence of myelosuppression.  AZT inhibition of DNA polymerases in bone 
marrow cells impairs haemopoietic cell production (60).   
 
Protease inhibitors form an important component of antiretroviral regimes.  
Yazdanpanah et al. (69) found that there was an increased incidence of bleeding 
in HIV positive patients with congenital coagulation disorders who were on 
lopinavir-ritonavir-containing antiretroviral regimes.  A mechanism for this bleeding 
has not been found, but may be associated with inhibition of the cytochrome P450 
system by disruption of prostaglandin-mediated platelet activation, or an enhanced 
fibrinolytic response (69, 70).  Ritonavir appears to be associated with the highest 
bleeding risk, followed by indinavir, and then saquinavir and nelfinavir.  Bleeding 
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usually occurs soon after commencement of therapy, and the risk of bleeding 
decreases with time on the agent.  Bleeding occurs into the joints or tissues and 
mucous membranes.  Some will only have excessive bleeding with surgery or 
dental extractions.  If severe the protease inhibitor is stopped and bleeding 
tendency resolves with time (70).  There have been reports of increased bleeding 
in patients who do not have a hereditary bleeding disorder.  Racoosin and Kessler 
(71) reported this, but found the incidence to be much lower than in the 
haemophiliac population.  Nielsen (72) reported hypermenorrhoea in a case 
series.  Lorenzi et al. (73) reported intracranial haemorrhage in two babies born to 
mothers on protease inhibitors.  These babies were premature, which could also 
be an explanation for the haemorrhage.  Koppel et al. (74) found increased levels 
of plasminogen activator inhibitor type 1 and fibrinogen in patients on protease 
inhibitors.  These increased levels alter the regulation of fibrinolysis. 
 
Protease inhibitor therapy has recently been implicated in deep vein thrombosis, 
pulmonary embolism, coronary artery disease and portal vein thrombosis.  
Protease inhibitors can thus result in a hyper- or hypocoagulable state.  
Hypercoagulability usually occurs at a mean of 72 days post initiation of therapy 
and is thought to be as a result of interference with hepatic regulation of 
coagulation proteins.  Agents implicated included ritonavir, indinavir, nelfinavir, and 
saquinavir (63).  Giuseppe (75) reported that 25% of patients on protease 
inhibitors have coagulation defects.  Endothelial dysfunction, and increased 
fibrinogen, d-dimer, plasminogen activator inhibitor-1 and tissue-type plasminogen 
activator antigen, and deficiency of protein S (reported in up to 73% of HIV positive 
men) have been implicated in these coagulation defects.  Coagulation side effects 
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of protease inhibitors occur less frequently than metabolic side effects.  However, 
those patients with fat redistribution syndrome have increased procoagulant levels 
in their blood samples and increased fibrinolysis.  It is suggested that the routine 
evaluation of coagulation is not advised until a benefit of screening is found.  An 
awareness of possible disorders is needed (75, 76). 
 
De Andrade et al. (77) showed an increase in bleeding at delivery of pregnant 
women on antiretroviral therapy.  The antiretroviral agents increased tissue 
plasminogen activator antigen and plasminogen activator inhibitor type 1 levels, 
which lead to hyperfibrinolysis. 
 
Suramin, dideoxyadenosine and dideoxyinosine are also myelosuppressive (60).  
Gancylovir, pentamidine and trimethoprim-sulfamethoxazole used to treat 
opportunistic infections associated with AIDS are bone marrow suppressant.  
 
2.2.5 Dentistry and HIV 
Early in the course of their disease 40-50% of HIV-infected persons will develop 
oral fungal, bacterial or viral infections (56).  These infections are often the first 
signs of immunosuppression and disease progression (78).  Early detection of oral 
disease and HIV testing and treatment can significantly decrease morbidity and 
mortality (79). 
 
Oral diseases include the following:  candidiasis, oral hairy leucoplakia, gingivitis, 
oral ulcers, Kaposi sarcoma, non-Hodgkin’s lymphoma, histoplasmosis, 
penicilliosis and xerostomia.   If treated early, the lack of these manifestations may 
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significantly improve the quality of life of HIV infected people (56, 80).  In a South 
African cohort oral candidiasis, angular chelitis and oral hairy leucoplakia were the 
most common oral lesions in HIV infected people (81). 
 
The dry mouth, as a result of decreased saliva, increases the incidence of dental 
caries (the saliva acts as a buffer to bacteria, contains secretory IgA, is a reservoir 
for calcium, phosphate and fluoride, and washes away plaque and food debris) 
and also decreases the quality of life as there is difficulty swallowing, chewing, 
tasting food, and speaking (7).  There are also halitosis and aesthetic problems.  
Arendorf et al. (82) found that more than 25% of HIV-infected patients had oral soft 
tissue disease that necessitated treatment. Diffuse Infiltrative Lymphocytic 
Syndrome and drugs used to treat HIV and opportunistic infections may also 
cause xerostomia (56, 78, 81). 
 
The mouth is a reservoir for pathogenic and non-pathogenic organisms.  In the 
immunosuppressed patient these organisms multiply rapidly to cause opportunistic 
infections.  There is a local spread of the pathogens and their toxins causing 
caries, necrotizing gingivitis, periodontitis, stomatitis, pharyngitis, and 
oesophagitis, or systemic spread causing blood and central nervous system 
infection (81). 
 
It is suspected that pathogens that would not usually cause widespread disease in 
the immunocompetant are the source of severe disease in HIV-positive people; 
especially as the CD4 lymphopenia worsens (81).  Silva-Boghossian et al. (78) 
investigated microorganisms in the saliva of HIV positive and negative children 
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and found that the majority of species tested for were more prevalent in the HIV 
negative group.  The incidence of bacteria in those children on ARVs and those 
not ARVs were similar, although ARVs and drugs used to treat opportunistic 
infections may modify microorganisms found in the mouth.  They found that HIV-
positive children were able to mount a mucosal immune response to oral 
pathogens.  An explanation of similar levels of salivary IgA in both groups was 
given. 
 
HIV positive patients have been observed to bleed more during dental procedures 
as a result of HIV disease process or the consequences of drug therapy (83). 
 
2.2.6 Paediatric patients and HIV 
The HIV/AIDS pandemic is severely affecting children.  Not only do they get sick, 
but also they are orphaned, suffer poverty and in many cases are deprived of a 
valuable, normal education (56).  Most children are infected by vertical 
transmission from mother to child (15-45% of children born to HIV infected 
mothers will become HIV positive if no specific interventions to prevent 
transmission are used (58)), some by household contact, sexual abuse or 
intercourse, blood product infusion, scarification, or by contaminated needles (4, 
84).  Of the 1500 daily new HIV infections in children, 9 out of 10 will be in sub-
Saharan Africa (84). 
 
Almost all children born to HIV positive women are HIV-antibody positive at birth.  
This antibody usually becomes undetectable between nine and eighteen months 
of age.  Infants less than 18 months are therefore diagnosed with HIV DNA 
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polymerase chain reaction, HIV peripheral blood culture and HIV p24 antigen, and 
not the standard anti-HIV IgG antibody tests used for older infants, children and 
adults (4).   
 
There are unique features of HIV infection acquired perinatally.  HIV-1 has very 
high replication rates that persist over time, and may lead to a rapidly progressive 
course towards AIDS with high viral loads.  The half-life of the virus is longer in 
infants less than three months than older infants.  It is thought that this is as a 
result of the immaturity of the immune system of infants (57, 85).  AIDS accounts 
for 3% of deaths in children less than five years old (84).  
 
As with adults, combination nucleoside protease inhibitor antiretroviral therapy is 
better than monotherapy.  Only 8% of patients receiving antiretroviral therapy in 
South Africa are children (84).  Three and four drug antiretroviral regimes have 
been found safe and effective in children, who experience greater immune 
recovery than adults because of an active thymus gland (57, 86).  Adherence to 
drug regimens and long-term complications are of concern (87).  Eligibility for 
ARVs has until recently been determined by clinical and immunological category, 
that is a CD4 percentage of less than 15 and/or a CDC clinical stage B or C (58).  
In 2010 the WHO published new recommendations for starting ARVs in children, 
as follows: 
• infants and children younger than two years old should start ARVs 
immediately on diagnosis 
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• children from two years old to five years old should be started on ARVs 
when the CD4 percentage is less than 25 or CD4 count is less than 750 
cells/mm3 
• children aged five or more should be started on ARVs when the CD4 count 
is less than 350 cells/mm3 (88).  
 
In 2008 fewer than 10% of children eligible for ARVs in sub-Saharan Africa were 
receiving these drugs, however, the WHO reported in December 2010 that this 
figure had risen to 21% (59, 89).  Drug dosages need to be altered for paediatric 
metabolism and often drugs are not prepared in a form easily taken by children.  
There is less research into antiretroviral agents in children than in adults (75). 
 
HIV affects many of the organ systems in children, however, little has been written 
about these manifestations.  The haematological system is commonly affected.  
Consolini et al (90) found that 35% of children in their study group presented with 
haematological manifestations of HIV, 21% of these with thrombocytopenia.  
Haematological manifestations include: anaemia (the most common manifestation 
after CD4 count decrease); neutropenia; lymphopenia; thrombocytopenia; and 
eosinophilia.  These manifestations are as a result of immune-mediated peripheral 
destruction of haematological cells, bone marrow infiltration, suppression and 
dysplasia, nutritional deficiencies, HIV replication, or medications (zidovudine, 
gancyclovir, trimethoprim-sulfamethoxazole) (4, 85, 90).  
 
Thrombocytopenia is one of the earliest manifestations of HIV infection in children, 
with up to 50% developing this complication before one year of age (it is, however, 
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rarely the first clinical sign of disease in children; 5,8% versus 10% in adults (90)).  
Others develop thrombocytopenia later in the disease process (9).  A study in 
Lagos, Nigeria showed that thrombocytopenic children have more advanced 
disease.  Although these results were not significant as the sample size was not 
large enough, they have also been shown in a CDC study (91).  Children with 
thrombocytopenia are placed in CDC clinical category B (4).  Consolini et al (90) 
found that children with anaemia and thrombocytopenia associated with HIV had a 
significantly worse prognosis than those without.  Children are unlikely to have any 
significant bleeding if the platelet count is more than 20-30x109/l.  It is suggested 
that the thrombocytopenia only be treated if there is significant bleeding (10).  The 
response of platelets to antiretroviral treatment in children has not been as good 
as in adults, and as with adults, AZT, didanosine, lamivudine and enfuvirtide have 
been shown to cause thrombocytopenia (4, 9, 92).  
 
Ellaurie (93) reported thrombocytosis (a platelet count of >500 x109/l) in 6% of 
children from a cohort of 400 patients.  There were no thrombotic complications 
with these patients.  It is thought that the chronic nature of the viral infection with 
HIV, as well as nutritional, metabolic, immune and neoplastic diseases, trauma, 
drugs, splenectomy, iron deficiency anaemia, and acute blood loss, may contribute 
to the aetiology of the thrombocytosis (92, 93). 
 
Dental caries in children is an important primary health care issue.  It is estimated 
that 40% of five year olds in the United Kingdom have had caries, making it the 
most common chronic disease in that country (5, 7).  In South Africa, the 
1999/2002 South African National Children’s Oral Health Survey published a 
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dental caries prevalence of 51% in four-to-five year olds (6).  The incidence in HIV 
positive children (in whom the incidence of xerostomia is higher than in adult 
infected patients) and those with other chronic disease is higher as a result of 
immunosuppression.  Although HIV positive children have a lower incidence of 
caries producing microorganisms (Streptococcus mutans, Streptococcus salivarius 
and Lactobacillus acidophilus) in their saliva, the incidence of caries is higher than 
in HIV negative children.  These children are also at risk for complications of 
caries, namely periodontal disease and systemic infection (7, 78, 80).  The most 
common oral manifestations in HIV positive children are oral candidiasis (angular 
chelitis, pseudomembranous, erythematous and hyperplastic), gingivitis, linear 
gingival erythema, parotid enlargement, herpes simplex and leucoplakia (78).  In 
immunocompromised children the risks associated with untreated caries and other 
oral infections necessitates the provision of preventative dental care (7). 
 
The issue of paediatric HIV disclosure has been studied in South Africa.  Moodley 
et al. (94) concluded that disclosure of HIV status might improve the quality of life, 
longevity, care and treatment of infected children. 
   
 
2.3 Conclusion 
This chapter has focused on a discussion of currently available literature on 
coagulation and HIV relevant to the study.   
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CHAPTER 3: RESEARCH METHODOLOGY 
 
This chapter will present the methodology for this research report. 
 
3.1 Problem statement 
It was observed clinically that children known to be HIV positive bled more than 
those with unknown or known negative status when undergoing dental extractions 
at CMJAH.  At the time of this research project there was no research determining 
whether these HIV positive children had abnormal coagulation profiles, as seen by 
an abnormal TEG or thrombocytopenia, and whether this was the reason for the 
observed increase in bleeding. 
 
3.2 Aims of the study 
This study was conducted in three parts: 
 
Part 1  
The aim of this part of the study was to determine if there was a difference in the 
coagulation profile of HIV positive paediatric patients (those on ARVs and those 
not on ARVs) and HIV negative paediatric patients undergoing dental extractions 
at CMJAH. 
 
Part 2 
The aim of this part of the study was to compare the CD4 counts and percentages 
of HIV positive paediatric patients on ARVs and those not on ARVs with that of the 
HIV negative paediatrics patients undergoing dental extractions at CMJAH. 
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Part 3  
The aim of this part of the study was to compare observed bleeding of the HIV 
positive paediatric patients (on ARVs and not on ARVs) with that of the HIV 
negative paediatric patients undergoing dental extractions at CMJAH. 
 
3.3 Objectives of the study 
The aims of the study were justified by the following objectives. 
 
Part 1 
• To describe the coagulation profile of HIV positive (on ARVs and not on 
ARVs) and HIV negative paediatric patients undergoing dental extractions. 
• To compare the coagulation profiles of these patients. 
 
Part 2 
• To determine the CD4 counts and percentages of HIV positive (on ARVs 
and not on ARVs) and negative paediatric patients undergoing dental 
extractions. 
• To compare the CD4 counts and percentages of the three groups. 
 
Part 3 
• To assess the observed bleeding in the HIV positive (on ARVs and not on 
ARVs) and the HIV negative groups of paediatric patients undergoing 
dental extractions. 
• To compare the observed bleeding between the groups. 
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3.4 Location of the study 
The study took place at the CMJAH, Gauteng Province, South Africa.  CMJAH is 
an academic hospital associated with the University of the Witwatersrand.  It is a 
tertiary hospital acting as a referral hospital for a number of smaller regional 
hospitals. 
 
3.5 Ethical considerations 
Ethical approval for the study was received from the HREC (Appendix 1) of the 
University of the Witwatersrand, Johannesburg, Gauteng Province, South Africa. 
 
Approval for the study was verbally obtained from the authorities at CMJAH. 
 
After discussion and explanation of the study and giving of an information packet, 
written informed consent was obtained from the parent or legal guardian of each 
patient prior to admission into the study.  Assent was sought from the patients who 
were six years old or older.  Appendices 2 to 8. 
 
Patients and their guardians who had an HIV test for the purposes of this study 
received pre- and post-test counselling. 
 
3.6 Study design 
A prospective, contextual, descriptive research design was followed in this study. 
 
Prospective: A prospective study design was chosen, as this determines how the 
factors under study relate to outcome in the cohort over time.  Evidence usually 
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ranks higher than that of retrospective studies, although prospective studies tend 
to be more time consuming and expensive (95, 96, 97). 
 
Contextual: This study is contextual as it was conducted within a specific context.  
De Vos (98) describes context as a small-scale world.  This study was conducted 
at CMJAH on children undergoing dental extractions. 
 
Descriptive: A descriptive design was chosen.  The primary purpose of this 
design is to develop a body of knowledge.  This study method provides a picture of 
situations as they naturally happen.  No manipulation of variables is involved; 
however, there is control over extraneous variables.  The setting for a descriptive 
study is therefore natural but conducting the study involves a high degree of 
control (99, 100). 
 
3.7 Study population 
The study population was all paediatric patients presenting for dental extraction at 
CMJAH. 
 
3.8 Study sample 
 
3.8.1 Sample statement 
In consultation with a biostatistician a sample size of 16 in each group was used.  
This sample had a 90% power to detect a difference in means of 4.0 (one 
standard deviation) assuming that the common deviation was 3.3 (reference) 
using a two group t-test with a 0.05 two-sided significance level (11, 12, 13). 
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3.8.2 Sampling method 
A consecutive, convenience sampling method was used in this study. 
 
The convenience sampling method was chosen because of the time constraints 
and the scope of the research.  The most readily accessible paediatric patients 
presenting for dental extractions were included.  It was acknowledged that a 
convenience sample cannot fully represent the study population (14). 
 
The study further used a consecutive sampling method where every paediatric 
patient who presents for dental extraction was invited to take part in the study.  
Consecutive sampling was the most reliable form of convenience sampling as 
research bias was limited (14). 
 
3.8.3 Inclusion criteria 
The following inclusion criteria were used for the study: 
• known HIV positive paediatric patients on antiretroviral treatment 
• known HIV positive paediatric patients not on antiretroviral treatment 
• HIV negative paediatric patients. 
 
3.8.4 Exclusion criteria 
The following exclusion criteria were used for the study: 
• refusal to give consent 
• HIV positive or negative paediatric patients’ known to have a coagulation 
abnormality. 
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3.9 Procedure for data collection 
The researcher identified potential patients to enrol in the study at the dental clinic. 
Known HIV positive patients were invited to take part in the study.  If they agreed, 
informed, signed consent was obtained from the parent or legal guardian and 
assent from those paediatric patients over six years old. Potential HIV negative 
patients were invited to take part in the study. If they agreed a CMJAH HIV 
councillor counselled them.  Consent for HIV testing was then obtained from the 
parent or legal guardian.  A blood sample for a rapid HIV test was taken and sent 
to NHLS laboratory at CMJAH for analysis. Once the results were known the 
hospital councillor counselled the parents again. All paediatric patients found to be 
HIV positive during data collection for this research report were referred to the 
CMJAH virology clinic for follow up treatment.  Signed informed consent was then 
obtained from the confirmed HIV negative patients’ parents and assent was 
obtained from paediatric patients of appropriate age.  See appendices two to eight 
for information given to the paediatric patients and their caregivers, as well as the 
consent and assent forms. 
 
The anaesthetics for the paediatric patients enrolled in the study were given by the 
consultant and registrar staff of the Department of Anaesthesiology at CMJAH.  
The researcher was present at the induction of anaesthesia for all enrolled 
paediatric patients and collected all the blood specimens for the study.  The 
paediatric patients received a general anaesthetic using the following standard 
anaesthetic technique: 
• the child was assessed on arrival in theatre 
• the parent accompanied the child into theatre for induction of anaesthesia 
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• standard anaesthetic monitors were applied to the patient (these were; an 
oxygen saturation probe, ECG monitoring, non-invasive blood pressure 
monitoring and a capnograph) 
• anaesthesia was induced by the inhalational method using sevoflurane. 
 
After anaesthesia was established, at the time of intravenous cannula insertion 
approximately 7 ml of blood was drawn from the child for the following tests: 
platelet count, CD4 count, CD4 percentage and TEG analysis. 
 
The platelet, CD4 count and CD4 percentage specimens were sent to the NHLS 
laboratory at CMJAH for analysis. The blood specimen for the TEG was 
immediately handed to the anaesthesiology technician for analysis. 
 
Specimens sent to the NLHS laboratory were analysed in a standard manner. The 
CMJAH NLHS laboratory is an accredited laboratory that adheres to Good 
Laboratory Research Practice.  
 
TEG analysis was done as follows: 
• 1 ml of whole blood was placed in a TEG kaolin tube 
• 340 µl of this blood was placed in the TEG cup with 20 µl of calcium 
chloride within 4-6 minutes of venesection 
• the cup was placed in the calibrated TEG machine and allowed to oscillate 
at 37°C 
• the TEG was allowed to run until the parameters being monitored were 
available. 
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One anaesthesiology technician performed the TEG analysis. The TEG machine 
was calibrated every day before the commencement of surgery.  The equipment 
(cups and pipette tips) required for analyses were all from the same batch and 
were stored in the department of anaesthesiology research office at room 
temperature.  The kaolin tubes were stored at constant temperature in the 
refrigerator in the research office.  
 
The following data was obtained and entered on a data capture sheet (Appendix 
9):  
• demographic data (name, hospital number, gender, and age) 
• American Society of Anaesthetists (ASA) classification 
• co-morbidities 
• HIV status 
• ARVs of HIV positive patients 
• concurrent medications that patient is receiving 
• blood results 
• surgical complications including significant bleeding 
• anaesthetic complications. 
 
The data was entered onto an Excel spreadsheet. 
 
The data collection procedure is illustrated in figure 3.1. 
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Figure 3.1 Flow diagram of the data collection procedure 
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1 ml blood into kaolin tube for 
TEG analysis 
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3.10 Statistical analysis 
Platelet counts, TEG parameters and CD4 counts and percentages are continuous 
and were summarized by patient group using mean, standard deviation and 95% 
confidence intervals.  The three groups were compared with respect to the 
individual platelet counts, TEG parameters and CD4 counts and percentages 
using a one-way analysis of variance (ANOVA) followed by pair wise comparison 
using the Bonferroni adjustment to address multiplicity.  To deal with big standard 
deviations and skewed data a one-way ANOVA for ranks was used to test for 
differences between the groups.   
 
Patient groups were compared with respect to bleeding complications using the 
Fisher’s exact test, while for CD4 counts the Welch t-test, adjusting for unequal 
variances, was employed.  These results were also confirmed using the Wilcoxon 
rank-sum test. 
 
Testing was done at the 0.05 level of significance. 
 
3.11 Validity and reliability 
The validity and reliability of the study were increased by the following measures. 
 
One anaesthesiology technician trained in TEG analysis did the TEG analysis for 
this study.  This was so that standard practices were adhered to and reliable 
results were obtained.  A single TEG machine (TEG®) was used to limit variance 
that might occur between machines.  The machine was calibrated to manufacturer 
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standards on each day that TEG analysis was performed to ensure accurate 
results were obtained. 
 
Blood specimens drawn for HIV testing, platelet count and CD4 count and 
percentage were sent to the NHLS laboratory at CMJAH.  In the laboratory Good 
Laboratory Research Practices are adhered to.  This ensured reliable results from 
these tests. 
 
The researcher, prior to analysis, collected all data.  This ensured that data was 
collected in a standard manner from reliable sources. 
 
Assessment of an increase in observed bleeding was subjective.  The reliability of 
this observation was increased as only one senior member of the Department of 
Paediatric Dentistry assessed bleeding in all the paediatric patients who had 
dental extractions. 
 
3.12 Conclusion 
In this chapter a detailed description of the research methodology used in this 
study was presented. 
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CHAPTER 4: RESEARCH RESULTS 
 
This chapter will present the results laid out by the objectives of the study and of 
the statistical analyses discussed in chapter three.  
  
4.1 Sample realisation 
Original consultation with the biostatistician recommended a sample size of 16 
paediatric patients in each of the three study groups, HIV negative, HIV positive 
not on ARVs and HIV positive on ARVs.  After two years of data collection only 12 
patients had been recruited in the HIV positive not on ARVs group.  These 
numbers were reviewed by the same biostatistician and found to be adequate for 
the purposes of this study. 
 
Seventy six paediatric patients between 2 and 11 years of age were enrolled in the 
study.  Of these children, 47 (61.84%) were HIV negative, 12 (15.79%) were HIV 
positive and not on ARVs and 17 (22.37%) were HIV positive and taking ARVs.   
 
4.2 Demographic data 
This study took place at CMJAH from November 2009 to November 2011.  
 
Six of the children were two-year-olds, 15 were three-year-olds, 19 were four-year-
olds, 14 were five-year-olds, eight were six-year-olds, three were seven-year-olds, 
six were eight-year-olds, three were nine-year-olds, one was 10 years old and one 
was 11 years old.  Figure 4.1 shows the total number of paediatric patients 
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enrolled divided by age; each age group is then further divided into those children 
who were HIV negative, HIV positive and HIV positive on ARVs. 
 
 
Figure 4.1 Ages of paediatric patients studied divided into HIV negative, HIV 
positive and HIV positive on ARVs categories 
 
The mean age of the paediatric patients in this study was 4.86 years with the 
range being 2 to 11 years.  There were an equal number of male and female 
paediatric patients enrolled. 
 
Of the paediatric patients enrolled in the study 45 (59.2%) were assessed as being 
ASA category 1 patients, 22 (29.0%) being ASA category 2 patients and nine 
(11.8%) as ASA category 3 patients. 
 
The mean number of teeth extracted from the paediatric patients was 9.67 (range 
1-20).  Of these teeth each patient had a mean of 4.55 single cusped teeth 
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(incisors and canines) extracted (range 0-12) and a mean of 5.12 multiple cusped 
teeth (molars) extracted (range 0-12). 
 
The mean number of single cusped teeth extracted from the paediatric patients in 
the HIV negative group was 3.62 (standard deviation (SD) 2.58).  The mean in the 
HIV positive group not on ARVs was 7.08 (SD 3.73) .  The mean in the HIV 
positive group on ARVs was 5.35 (SD 2.96).  Using one-way ANOVA for ranks 
with the Bonferroni adjustment to address multiplicity a p-value of 0.002 was 
obtained, indicating a statistically significant difference.  Comparing the three 
groups by rank, the differences were found to be between the HIV negative group 
and the HIV positive group not on ARVs (p = 0.006) and between the HIV negative 
group and the HIV positive group on ARVs (p = 0.048). 
 
The mean number of multiple cusped teeth extracted from the paediatric patients 
in the HIV negative group was 4.83 (SD 2.40).  The mean in the HIV positive 
group not on ARVs was 6.00 (SD 3.10).  The mean in the HIV positive group on 
ARVs was 5.94 (SD 2.51).  Using one-way ANOVA for ranks with the Bonferroni 
adjustment to address multiplicity a p-value of 0.222 was obtained.  The difference 
in number of multiple cusped teeth extracted between the groups was not 
statistically significant.   
 
This data is summarised in table 4.1 
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Table 4.1 Summary of extracted teeth 
  n 
mean single-
cusped teeth 
SD single 
cusped teeth 
mean multiple 
cusped teeth 
SD multiple 
cusped teeth 
HIV negative 47 3.62 2.58 4.83 2.40 
HIV positive 
not on ARVs 12 7.08 3.73 6.00 3.10 
HIV positive 
on ARVs 17 5.35 2.96 5.94 2.51 
    
p = 0.002   p = 0.222   
 
 
4.3  The coagulation profiles of the paediatric patients studied 
Part 1 of the study objectives was to describe the coagulation profile of the HIV 
positive patients (on ARVs and not on ARVs)  and the HIV negative patients and 
then to compare the coagulation profiles.  This included platelet counts and TEG 
parameters (r-time, K-time, α-angle and MA). 
 
4.3.1  Platelet count 
None of the paediatric patients enrolled in this study had platelet counts less than 
the thrombocytopenia threshold defined in chapter 1 (150 x109/l). 
 
The mean platelet count of the HIV negative patients was 375.87 x109/l, the SD 
89.05 and the 95% confidence interval (95% CI) 350.41 to 401.33.   
 
The mean platelet count of the HIV positive patients not on ARVs was 407.00 
x109/l, the SD 117.30 and the 95% CI 340.63 to 473.37.   
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The mean platelet count of the HIV positive group on ARVs was 343.18 x109/l, the 
SD 87.58 and the 95% CI 301.54 to 384.81.   
 
One-way analysis of variance for ranks, using the Bonferroni adjustment to 
address multiplicity, of the three groups did not show a statistically significant 
difference ( p = 0.2087). 
 
This data is summarised in table 4.2 below. 
 
Table 4.2 Summary of description of platelet count results 
Group  n platelet count 
mean 
platelet count 
SD  
95% CI lower 
limit 
95% CI upper 
limit 
HIV 
negative 47 375.87 89.05 350.41 401.33 
HIV positive 
not on ARVs 12 407.00 117.30 340.63 473.37 
HIV positive 
on ARVs 17 343.18 87.58 301.54 384.81 
  
        p = 0.2087 
 
 
4.3.2  Thromboelastogram r-time 
The mean TEG r-time of the HIV negative patients was 5.04 minutes, the SD 3.40 
and the 95% CI 4.17 to 5.91. 
 
The mean TEG r-time of the HIV positive patients not on ARVs was 5.51 minutes, 
the SD 2.73 and the 95% CI 3.96 to 7.05. 
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The mean TEG r-time of the HIV positive group on ARVs was 4.87 minutes, the 
SD 4.60 and the 95% CI 2.68 to 7.05. 
 
One-way analysis of variance for ranks, using the Bonferroni adjustment to 
address multiplicity, of the three groups did not show a statistically significant 
difference (p = 0.4738). 
 
This data is summarised in table 4.3 below. 
 
Table 4.3 Summary of description of TEG r-time results 
Group  n TEG r-time 
mean 
TEG r-time SD  95% CI lower limit 
95% CI upper 
limit 
HIV 
negative 47 5.04 3.40 4.17 5.91 
HIV positive 
not on ARVs 12 5.51 2.73 3.96 7.05 
HIV positive 
on ARVs 17 4.87 4.60 2.68 7.05 
  
        p = 0.4738 
 
 
4.3.3 Thromboelastogram K-time 
The mean TEG K-time of the HIV negative patients was 1.53 minutes, the SD 0.98 
and the 95% CI 1.25 to 1.81. 
 
The mean TEG K-time of the HIV positive patients not on ARVs was 1.53 minutes, 
the SD 0.49 and the 95% CI 1.25 to 1.81. 
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The mean TEG K-time of the HIV positive group on ARVs was 1.72 minutes, the 
SD 1.35 and the 95% CI 1.08 to 2.36. 
 
One-way analysis of variance for ranks, using the Bonferroni adjustment to 
address multiplicity, of the three groups did not show a statistically significant (p = 
0.6967). 
 
This data is summarised in table 4.4 below. 
 
Table 4.4 Summary of description of TEG K-time results 
Group  n TEG K-time 
mean 
TEG K-time 
SD  
95% CI lower 
limit 
95% CI upper 
limit 
HIV 
negative 47 1.53 0.98 1.25 1.81 
HIV positive 
not on ARVs 12 1.53 0.49 1.25 1.81 
HIV positive 
on ARVs 17 1.72 1.35 1.08 2.36 
  
        p = 0.6967 
 
 
4.3.4 Thromboelastogram α-angle 
The mean TEG α-angle of the HIV negative patients was 68.12 degrees, the SD 
8.78 and the 95% CI 65.61 to 70.63. 
 
The mean TEG α-angle of the HIV positive patients not on ARVs was 69.46 
degrees, the SD 5.82 and the 95% CI 66.16 to 72.75. 
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The mean TEG α-angle of the HIV positive group on ARVs was 69.18 degrees, the 
SD 9.65 and the 95% CI 64.59 to 73.77. 
 
One-way analysis of variance for ranks, using the Bonferroni adjustment to 
address multiplicity, of the three groups did not show a statistically significant 
difference (p = 0.7948). 
 
This data is summarised in table 4.5 below. 
 
Table 4.5 Summary of description of TEG α-angle results 
Group  n TEG α-angle 
mean 
TEG α-angle 
SD  
95% CI lower 
limit 
95% CI upper 
limit 
HIV 
negative 47 68.12 8.78 65.61 70.63 
HIV positive 
not on ARVs 12 69.46 5.82 66.16 72.75 
HIV positive 
on ARVs 17 69.18 9.65 64.59 73.77 
  
        p = 0.7948 
 
 
4.3.5 Thromboelastogram MA  
The mean TEG MA of the HIV negative patients was 71.09 mm, the SD 8.41 and 
the 95% CI 68.69 to 73.50. 
 
The mean TEG MA of the HIV positive patients not on ARVs was 72.78 mm, the 
SD 6.43 and the 95% CI 69.15 to 76.42. 
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The mean TEG MA of the HIV positive group on ARVs was 69.08 mm, the SD 
8.42 and the 95% CI 65.07 to 73.08. 
 
One-way analysis of variance for ranks, using the Bonferroni adjustment to 
address multiplicity, of the three groups did not show a statistically significant 
difference (p = 0.2982). 
 
This data is summarised in table 4.6 below. 
 
Table 4.6 Summary of description of TEG MA results 
Group  n TEG MA mean TEG MA SD  95% CI lower limit 
95% CI upper 
limit 
HIV 
negative 47 71.09 8.41 68.69 73.50 
HIV positive 
not on ARVs 12 72.78 6.43 69.15 76.42 
HIV positive 
on ARVs 17 69.08 8.42 65.07 73.08 
          
p = 0.2982 
 
 
4.4  The CD4 count and percentage of the study group 
Part 2 of the study objectives was to determine and then compare the CD4 count 
and percentage of the paediatric patients enrolled in the study. 
 
4.4.1  CD4 count 
The mean CD4 count of the patients in the HIV negative group was 1227.64 
x106/l, with a SD of 419.10.  The 95% CI was 1107.82 to 1347.46. 
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The mean CD4 count of the patients in the HIV positive group not on ARVs was 
686.08 x106/l, with a SD of 263.16.  The 95% CI was 537.19 to 834.98. 
 
The mean CD4 count of the patients in the HIV positive group on ARVs was 
1234.71 x106/l, with a SD of 621.08.  The 95% CI was 939.47 to 1529.95. 
 
Comparing the three groups using one-way ANOVA for ranks and the Bonferroni 
adjustment to address multiplicity, a statistically significant difference was found (p 
= 0.0002). 
 
These results are summarised in table 4.7. 
 
Table 4.7  Summary of the description of results for CD4 count 
Group  n CD4 count 
mean 
CD4 count SD  95% CI lower limit 
95% CI upper 
limit 
HIV 
negative 47 1227.64 419.10 1107.82 1347.46 
HIV positive 
not on ARVs 12 686.08 263.16 537.19 834.98 
HIV positive 
on ARVs 17 1234.71 621.08 939.47 1529.95 
  
        p = 0.0002 
 
 
A comparison for rank showed that the differences were between the HIV negative 
group and the HIV positive group not on ARVs (p = 0.000) and between the HIV 
positive group on ARVs and the HIV positive group not on ARVs (p = 0.004).  The 
was no statistically significant difference between the HIV negative and HIV 
positive on ARVs groups (p = 1.0000). 
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4.4.2  CD4 percentage 
The mean CD4 percentage of the patients in the HIV negative group was 30.55%, 
with a SD of 6.28.  The 95% CI was 28.76 to 32.35. 
 
The mean CD4 percentage of the patients in the HIV positive group not on ARVs 
was 15.83%, with a SD of 3.99.  The 95% CI was 13.57 to 18.08. 
 
The mean CD4 percentage of the patients in the HIV positive group on ARVs was 
25.44%, with a SD of 6.31.  The 95% CI was 22.44 to 28.44. 
 
Comparing the three groups using one-way ANOVA for ranks and the Bonferroni 
adjustment to address multiplicity, a statistically significant difference was found (p 
= 0.0000). 
 
These results are summarised in table 4.8. 
 
Table 4.8  Summary of the description of results for CD4 percentage 
Group  n CD4 % mean CD4 % SD  95% CI lower limit 
95% CI upper 
limit 
HIV 
negative 47 30.55 6.28 28.76 32.35 
HIV positive 
not on ARVs 12 15.83 3.99 13.57 18.08 
HIV positive 
on ARVs 17 25.44 6.31 22.44 28.44 
  
        p = 0.0000 
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A comparison for rank showed that the differences were between the HIV negative 
group and the HIV positive group not on ARVs (p = 0.000), between the HIV 
positive group on ARVs and the HIV positive group not on ARVs (p = 0.001) and 
between the HIV negative group and the HIV positive group on ARVs (p = 0.013).   
 
4.5  Assessment of bleeding 
Part 3 of the study objectives was to assess the observed bleeding after dental 
extraction in the three groups of paediatric patients and then to compare the 
bleeding. 
 
Twenty-two (28.95%) patients were considered by the dentist to have increased 
bleeding after dental extraction.  None of the bleeding was significant in terms of 
the study definition. 
 
Of the 22 patients with increased bleeding, ten were in the HIV negative group, six 
in the HIV positive group not on ARVs and six in the HIV positive group on ARVs. 
 
This data is graphically represented in figure 4.2 below. 
68 
 
 
Figure 4.2 Pie chart of the number of patients assessed to have increased 
bleeding. 
 
Using the Fisher’s exact and one-sided Fisher’s exact tests the numbers of 
bleeding patients in each group were found not to be statistically significant (p-
values ranged from 0.054 to 0.101). 
 
The group of HIV positive patients was then assessed as a whole for bleeding.  
The total number of HIV positive patients was 29.  Of these 12 (41.38%) had an 
observed increase in the amount of bleeding (bleeders) and 17 (58.62%) did not 
(non-bleeders).  These two groups (bleeders and non-bleeders) were then 
compared in terms of CD4 count.   
 
The mean CD4 count of all the HIV positive paediatric patients was 1007.69 x106/l.  
The SD was 568.55.  The 95% CI was 791.43 to 1223.95. 
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The mean CD4 count of the bleeders was 727.83 x106/l.  The SD was 332.52.  
The 95% CI was 516.56 to 939.11. 
 
The mean CD4 count of the non-bleeders was 1205.24 x106/l.  The SD was 
624.06.  The 95% CI was 884.37 to 1526.10. 
 
A two-sample Welsh t-test with unequal variances was used to show that those 
patients who bled had lower CD4 counts. This was statistically significant (p = 
0.0129). 
 
This data is summerised in table 4.9 below. 
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Table 4.9 Summary of data comparing HIV positive patients and CD4 count 
Group (HIV 
positive) n 
CD4 count 
mean 
CD4 count 
standard 
error  
CD4 count 
SD  
CD4 count 
95% CI lower 
limit  
CD4 count 
95% CI upper 
limit  
 Increased 
bleeding 
observed 
12 727.83 95.99 332.52 516.56 939.11 
No 
increase in 
bleeding 
observed 
17 1205.24 151.36 624.06 884.37 1526.10 
All HIV 
positive 
paediatric 
patients 
29 1007.69 105.58 568.55 791.43 1223.95 
Difference 
  -477.40 179.23   -845.21 -109.60 
  
          
p = 0.0129 
 
The non-parametric Wilcoxon rank-sum (Mann-Whitney) test also confirmed that 
the bleeding group had significantly lower CD4 counts  (p = 0.0335).   
 
4.6 Conclusion  
The research results presented in this chapter describe the data collected and 
statistical analyses needed to satisfy the aims and objectives of the research.   
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CHAPTER 5: DISCUSSION OF RESEARCH RESULTS 
 
In this chapter the results presented in the previous chapter will be interpreted and 
discussed in accordance with the problem statement, aims and objectives of the 
study. 
 
5.1 Sample realisation 
Original consultation with the biostatistician recommended a sample size of 16 
paediatric patients in each of the three study groups, HIV negative, HIV positive 
not on ARVs and HIV positive on ARVs.  After two years of data collection only 12 
patients had been recruited in the HIV positive not on ARVs group.  These 
numbers were reviewed by the same biostatistician and found to be adequate for 
the purposes of this study. 
 
Possible reasons for the low numbers recruited in this group included: 
• the prompt commencement for ARVs on diagnosis of HIV, thus limiting 
global numbers in this group 
• fear of stigmatisation, thus non-disclosure of known status or refusal of 
consent to HIV testing 
• overburdened caregivers not having the capacity to bring these children for 
dental treatment. 
 
5.2 Demographic data 
The age distribution of children in this study is in keeping with the 1999/2002 
South African National Children’s Oral Health Survey (6).  In that survey it was 
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found that 51% of four to five years olds had dental caries.  In this study most of 
the children (63%) were in the three to five year old age bracket. 
 
The incidence of dental caries is higher in HIV positive children than in HIV 
negative children (78, 80).  In this cohort, more single cusped teeth were extracted 
from both HIV positive groups when compared to the HIV negative group (p = 
0.006) (although the difference in the number of multiple cusped teeth extracted 
was not statistically significant in this sample), showing that this group indeed 
followed the global trend, with the incidence of dental caries being higher in the 
HIV positive children. 
 
According to Oswald et al. (50) there is no gender difference in ROTEM® profiles 
in children less than 16 years of age, thus the paediatric patients in this study were 
not divided into male and female groups for statistical analysis. 
 
5.3 Part 1 
Part 1 of the study aimed to determine if there was a difference in the coagulation 
profiles of HIV negative and HIV positive children (on ARVs and not on ARVs) 
undergoing dental extractions at CMJAH.  A description and statistical analysis of 
the results of the platelet count and TEG profiles of these groups was presented in 
Chapter 4.   
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No statistically significant differences were found when comparing: 
- platelet count 
- TEG r-time 
- TEG K-time 
- TEG α-angle 
- TEG MA. 
 
Studies have shown that TEG abnormalities will only be apparent if 
thrombocytopenia exists (16, 27, 42).  As no patients in this study had 
thrombocytopenia, this may explain why there were no statistically significant TEG 
changes between the HIV negative, HIV positive on ARVs and HIV positive not on 
ARVs groups.  A previous study showed 21% of HIV positive patients to be 
thrombocytopenic; however, this was not the case in this study (90). 
 
5.4 Part 2 
Part 2 of the study aimed to compare the CD4 counts and percentages of the HIV 
positive paediatric patients on ARVs and those not on ARVs and that of HIV 
negative paediatric patients undergoing dental extractions at CMJAH.  Here a 
statistically significant difference was found. 
 
The differences in CD4 count between the HIV negative and HIV positive not on 
ARVs, and the HIV positive on ARVs and HIV positive not on ARVs groups, were 
both found to be statistically significant (p = 0.000 and 0.004). 
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The difference between the mean CD4 count of the HIV negative group and the 
HIV positive on ARVs group was 7.068 (p = 1.000).  This was not statistically 
significant.   
 
The use of ARVs in the HIV positive on ARVs group is thus seen to increase the 
CD4 count to the same mean as the HIV negative group, indicating the 
effectiveness of the treatment modality in the group.  This is consistent with 
worldwide indicators of clinical success and normalisation of prognosis to that of 
HIV negative individuals (67).  
 
5.5 Part 3 
The aim of Part 3 of the study was to compare observed bleeding of the HIV 
positive patients (on ARVs and not on ARVs) with that of the HIV negative 
paediatric patients undergoing dental extractions at CMJAH. 
 
On initial analysis of the data and comparison only between the three stipulated 
groups, no statistically significant difference was found to exist between the HIV 
negative, HIV positive on ARVs and the HIV positive not on ARVs groups.  
However, on further analysis, taking the observed bleeding into account and 
comparing it to the CD4 count in the entire HIV positive group (regardless of 
whether the paediatric patient was taking ARVs or not), it was found that those 
patients with a lower CD4 count bled more than those with a higher CD4 count (p 
= 0.0129 and 0.0335).   
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From the data collected in the study and the analysis thereof, it can be seen that in 
the group of paediatric patients (divided into HIV negative and HIV positive on 
ARVs and not on ARVs) there was no statistical significance in the difference 
between the platelet count and TEG profile.  As was expected, there was a 
statistically significant difference in the CD4 count between the HIV negative and 
HIV positive group not on ARVs and also between the HIV positive not on ARVs 
group and the HIV positive on ARVs group.  There was no statistically significant 
difference in the bleeding observed between these three study groups, but within 
the whole HIV positive group more bleeding was observed in those patients with 
lower CD4 counts.  The answer to the question, “why do those with lower CD4 
counts bleed more?” begs further analysis of the data which was not within the 
scope of this research report and further study.   
 
In commenting on the problem statement for this research report, it can be stated 
that not all HIV positive paediatric patients bleed more than those with known 
negative or unknown status.  Those HIV positive paediatric patients with lower 
CD4 counts bleed more than those whose CD4 counts are the same as or 
approaching that of HIV negative patients.  The data and the analysis thereof done 
within the scope of this research report, does not answer the question whether the 
HIV positive paediatric patients with lower CD4 counts had abnormal coagulation 
profiles.  All patients had platelet counts within the normal range for the laboratory 
and there was no statistically significant difference between the TEG profiles of the 
three study groups. 
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In conclusion, HIV positive children with lower CD4 counts are observed to bleed 
more than those with higher and normal CD4 counts.  That is those with 
progression of HIV/AIDS disease bleed more.  Further research is needed to 
determine the reason for the bleeding. 
 
5.6 Conclusion 
In this chapter a discussion and interpretation of the results presented in chapter 4 
was provided.  
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
This chapter will summarise and conclude the research report, in doing so it will 
refer to the problem statement, aims and objectives of the study.  Reference to the 
limitations of the study and recommendations for further research will then be 
made. 
 
6.1 Summary 
Paediatric HIV/AIDS remains a significant health care challenge in South Africa.  
Oral health and coagulation are only two of the many problems experienced by 
HIV positive paediatric patients. 
 
This research report began with an observation that known HIV positive paediatric 
patients bled more than known HIV negative paediatric patients or those with 
unknown HIV status while undergoing dental extractions at CMJAH.  The 
observation prompted a prospective, contextual, descriptive study looking at the 
coagulation profile (platelet count and TEG profile (r-time, K-time, α-angle and 
MA), CD4 counts and percentages and observed clinical bleeding in HIV negative, 
HIV positive not on ARVs and HIV positive on ARVs paediatric patients presenting 
for dental extraction. 
 
Over a two year period 47 HIV negative, 12 HIV positive not on ARVs and 17 HIV 
positive on ARVs paediatric patients were enrolled in the study using a 
consecutive, convenience sampling method.  Each paediatric patient was given a 
standard inhalational general anaesthetic using sevoflurane and during 
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intravenous cannulation the researcher drew blood from each child for analysis.  A 
senior dentist from the Department of Paediatric Dentistry assessed bleeding in all 
cases.  
 
The data obtained for each of the three study groups was compared using a one-
way ANOVA followed by pair wise comparison using the Bonferroni adjustment to 
address multiplicity.  To deal with the big standard deviations and skewed data a 
one-way ANOVA for ranks tested for differences between the groups.  No 
statistically significant differences were found when comparing the groups for 
platelet count (p = 0.2087), TEG r-time (p = 0.4738), TEG K-time (p = 0.6967), 
TEG α-angle (p = 0.7948) or TEG MA (p = 0.2982).  There was a statistically 
significant difference between the HIV negative and HIV positive not on ARVs 
groups (p = 0.000 and 0.004) and HIV positive on ARVs and HIV positive not on 
ARVs groups (p = 0.000 and 0.001) when comparing CD4 count and percentage.   
 
Patient groups were compared with respect to bleeding complications using the 
Fisher’s exact test.  There was no statistically significant difference in observed 
bleeding between the three groups of paediatric patients.  The entire HIV positive 
group was then compared for bleeding, and using the Welch t-test, adjusting for 
unequal variances it was found that there was statistically significantly more 
bleeding in the HIV positive children with lower CD4 counts regardless of 
treatment with ARVs (p = 0.0129).  These results were also confirmed using the 
Wilcoxon rank-sum test (p = 0.0335).   
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Although this study showed a statistically significant difference between bleeding 
in the HIV positive paediatric patients with lower CD4 counts (when compared to 
HIV positive paediatric patients with higher or normal CD4 counts), the tests of 
coagulation used in the study do not show why this bleeding occurs.  Further 
research into coagulation in HIV positive paediatric patients is needed. 
 
6.2 Conclusions 
This research report began with an observation.  The clinical observation was 
made that know HIV positive paediatric patients bled more than those with known 
negative or unknown status.  After data analysis this observation, in this group of 
patients has been found to be invalid.  HIV positive children do not bleed more 
than HIV negative children. 
 
Within the HIV positive group, however, those children with more advanced 
disease, as evidenced by a lower CD4 count, are observed to bleed more than 
those with early or treated disease.  
 
In answering part 1 of the aims and objectives of the study, no statistically 
significant difference was found in the coagulation profiles of the three groups of 
patients. 
 
A statistically significant difference in the CD4 count of the HIV negative and HIV 
positive on ARVs group versus the HIV positive group not on ARVs was found.  
This satisfies part 2 of the study aims and objectives. 
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No statistically significant difference was found when comparing the observed 
bleeding between the HIV positive patients on ARVs with those not on ARVs and 
the HIV negative paediatric patients.  This fulfils part 3 of the aims and objectives 
of the study. 
 
Further analysis of the data for observed bleeding found that within the entire 
group of HIV positive patients, the children with a lower CD4 count bleed more 
than those with a higher or normal count.  The analysis done (within the scope of 
this research report) on the data collected for this study does not give a 
biochemical explanation for this.  The TEG does not test for specific factor 
deficiencies which may be present in more advanced disease as a result of bone 
marrow suppression, liver disease or opportunistic infection amongst other 
causes.  Vascular and collagen function were not considered as causes for 
increased bleeding in this group in this study. 
 
6.3 Limitations 
The study was done contextually at CMJAH.  This context may not allow for 
generalisation of the results of the study, however, it was an important study to be 
done in that context as it addressed an observed problem. 
 
The limited number of study subjects in this research report could affect the ability 
to generalise the study results.  A biostatistician was consulted regarding whether 
the small number of study subjects had adequate power to detect a difference in 
means and a 90% power was found.  Even though the sample size was small in 
this negative study, the study may provide a baseline to direct further research. 
81 
 
 
A further limitation of this small study is that randomisation and sample selection 
could be biased.  For this reason a consecutive sampling method was used and 
the bias was limited.  
 
The assessment of clinical bleeding was subjective; however, one, blinded, senior 
dentist from the Department of Paediatric Dentistry at CMJAH assessed all the 
paediatric patients for bleeding.  In this way the subjectivity of this observation, 
and the bias of the dentist, was reduced and standardised. 
 
Dental caries is more prevalent in HIV positive children than in HIV negative 
children.  Although there was no statistically significant difference in the number of 
multiple cusped teeth extracted from each group, there were statistically 
significantly more single cusped teeth extracted from both HIV positive groups 
when compared to the HIV negative group.  The extraction of more teeth may 
have led to more bleeding; a possible limitation to the study.  However, as there is 
more caries in HIV positive children, it may not be possible to adjust for this 
limitation in any study. 
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6.4 Recommendations 
For the purposes of this research report, the platelet count and TEG profile were 
chosen to assess coagulation.  Future research may need to include individual 
coagulation factors as part of the coagulation profile and perhaps also look at 
vascular function and collagen.  This may show the reason for the observed 
increase in bleeding in HIV positive paediatric patients. 
 
Further statistical analysis of this data comparing each individual HIV positive 
patient regardless of treatment with ARVs (for platelet count and TEG parameters) 
may reveal why those with lower CD4 counts bled more. 
 
A more in depth look at the coagulation profile of each individual child with 
increased bleeding is recommended.  This analysis should include a review of any 
co-morbid medical conditions in these children as well as scrutinising any drug 
therapies they may be on, including ARVs. 
 
Those patients with more advanced disease, as evidenced by the lower CD4 
count, may have other co-morbid disease which affects platelet function (not 
assess by the TEG) or involvement of the liver in a process which affects clotting 
factor production.  These questions are not answered by the limited scope of this 
study. 
 
The collection of data was protracted in this study for a number of reasons.  The 
most striking of which was the lower numbers of HIV positive patients than 
expected.  Reasons were postulated, some being the effective use of ARVs to 
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prevent mother to child transmission of HIV (a number of positive mothers had 
children who tested negative), the stigma attached to disclosing HIV status and the 
fear of testing for HIV in a society where the prevalence of HIV is so high.  It was 
observed that parents and guardians of paediatric patients already taking ARVs 
we most eager to give consent for admission into the study.  Future studies should 
include investigation into the social circumstances of the paediatric patients as this 
may well answer some of the questions related to the low number of HIV positive 
children not on ARVs recruited into the study. 
 
The researcher agrees with the findings of Moodley et al. (94) that disclosure of 
HIV status and destigmatisation of the disease may well improve the life 
expectancy and quality of life of children living with HIV. 
 
This study and research report should be viewed as a pilot study for further 
research into coagulation in HIV positive children. 
 
6.5 Conclusion 
This chapter has summarised and concluded the study. It then made reference to 
the limitations of the study.  Finally recommendations for further analysis of the 
collected data and future research were made. 
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Appendix 1: HREC approval 
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Appendix 2: Information packet – parent/caregiver (HIV positive) 
 
Dear parent/caregiver 
 
Hello, my name is Anne Zeijlstra and I am a doctor at Johannesburg Hospital.  I make 
people sleep and pain free for operations.  As part of my Master’s degree in anaesthetics I 
am studying bleeding and blood clotting in children.  I want to compare clotting in HIV 
positive children and HIV negative children when they have teeth taken out under 
anaesthetic.  The anaesthetic is a deep sleep during which the surgery is done.  During 
this sleep your child will not feel any pain. 
 
HIV is short of Human Immunodeficiency Virus.  HIV can infect children.  Most children 
get infected with HIV when they are still in their mothers’ womb, during birth, or from 
breastfeeding.  Once HIV is in the body it attacks the immune system, which fights 
infection.  Antiretroviral drugs are medicines that can slow this attack down.  The virus and 
these medicines can change the way the blood clots.  It is this change that I want to study. 
 
If your child takes part in this study he/she will be made to sleep for the operation, just as 
we make children sleep for operations every day, by breathing an anaesthetic gas.  Every 
child who is asleep for an operation has a drip put in his/her arm or hand.  This will be no 
different for your child.  At the time that the drip is put in, one-and-a-half teaspoons of 
blood will be taken from your child for testing.  This blood will have three tests done on it: 
1. A test for the number of cells that make the blood clot (platelet count) 
2. A test for cells that are part of the immune system that fights infection (CD4 count) 
3. A test for how well the blood clots (Thromboelastogram). 
 
Your child’s operation will carry on in the same way, as it would have even if your child 
were not part of this study.  If you do not want your child to be part of the study, the 
treatment and care your child gets will not change in any way. 
 
The study will be anonymous.  Confidentiality will be maintained.  No names will be put in 
any of the results of the study. 
 
If you are willing to allow your child to participate in the study, you will need to sign a 
CONSENT FORM.  If your child is 6 years of age or more I will also ask his/her 
permission and he/she will be asked to sign an ASSENT FORM.   
 
Please understand that you can withdraw from the study any time without having to give a 
reason. The study is completely voluntary and not taking part in it or withdrawing from it, 
carries no penalty or repercussion of any sort. 
 
Before giving permission please be sure that you understand what we are testing.  If you 
are unsure we will make sure that someone is available to answer your questions in your 
home language.  Please feel free to ask any questions at any time during the process. 
 
Thank you. 
 
Anne Zeijlstra 
Anaesthetic Doctor 
86 
 
Appendix 3: Information packet – parent/caregiver (HIV unknown/HIV 
negative) 
Dear parent/caregiver 
 
Hello, my name is Anne Zeijlstra and I am a doctor at Johannesburg Hospital.  I make people 
sleep and pain free for operations.  As part of my Master’s degree in anaesthetics I am 
studying bleeding and blood clotting in children.  I want to compare clotting in HIV positive 
children and HIV negative children when they have teeth taken out under anaesthetic.  The 
anaesthetic is a deep sleep during which the surgery is done.  During this sleep your child 
will not feel any pain. 
 
HIV is short of Human Immunodeficiency Virus.  HIV can infect children.  Most children get 
infected with HIV when they are still in their mothers’ womb, during birth, or from 
breastfeeding.  Once HIV is in the body it attacks the immune system, which fights infection.  
Antiretroviral drugs are medicines that can slow this attack down.  The virus and these 
medicines can change the way the blood clots.  It is this change that I want to study. 
 
If your child takes part in this study he/she will be made to sleep for the operation, just as 
we make children sleep for operations every day, by breathing an anaesthetic gas.  Every 
child who is asleep for an operation has a drip put in his/her arm or hand.  This will be no 
different for your child.  At the time that the drip is put in, one-and-a-half teaspoons of blood 
will be taken from your child for testing.  This blood will have three tests done on it: 
A test for the number of cells that make the blood clot (platelet count) 
A test for cells that are part of the immune system that fights infection (CD4 count) 
A test for how well the blood clots (Thromboelastogram). 
 
A group of children whom we know are HIV positive are taking part in this study, but in 
order to know whether there is a difference between HIV positive and HIV negative children 
we need to test a group of children who are negative for HIV to be sure that they are HIV 
negative.  It is for this reason that I need your permission to test your child’s blood to make 
sure that he/she can be included in the HIV negative group of children. 
 
Your child’s operation will carry on in the same way, as it would have even if your child 
were not part of this study.  If you do not want your child to be part of the study, the 
treatment and care your child gets will not change in any way. 
 
The study will be anonymous.  Confidentiality will be maintained.  No names will be put in 
any of the results of the study. 
 
If you are willing to allow your child to participate in the study, you will need to sign a 
CONSENT FORM.  If your child is 6 years of age or more I will also ask his/her permission 
and he/she will be asked to sign an ASSENT FORM.   
 
Please understand that you can withdraw from the study any time without having to give a 
reason. The study is completely voluntary and not taking part in it or withdrawing from it, 
carries no penalty or repercussion of any sort. 
 
Before giving permission please be sure that you understand what we are testing.  If you are 
unsure we will make sure that someone is available to answer your questions in your home 
language.  Please feel free to ask any questions at any time during the process. 
 
Thank you. 
 
Anne Zeijlstra 
Anaesthetic Doctor 
Telephone number: 011 488 4397 
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Appendix 4: Consent form  
 
Research Title: Coagulation profiles of HIV-positive and -negative paediatric 
patients undergoing dental extractions at the Johannesburg Hospital. 
 
 
I ______________________________ understand what this study is about and 
give consent of my child/the child I care for to participate in this study.  I have read 
and understand the information sheet and my questions have been answered.  I 
am aware that the procedures will not harm the child in any way.  I am aware that 
the child may withdraw from the study at any time without any prejudice toward the 
child or me.  I understand that my name and that of my child will not appear in any 
of the results of the research. 
 
 
 
 
________________________ 
Parent/Caregiver name 
 
 
________________________ 
Parent/Caregiver signature 
 
 
________________________ 
Date 
 
 
 
 
________________________ 
Researcher name 
 
 
________________________ 
Researcher signature 
 
 
________________________ 
Date 
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Appendix 5: Consent form (HIV testing) 
 
Research Title: Coagulation profiles of HIV-positive and -negative paediatric patients 
undergoing dental extractions at the Johannesburg Hospital. 
 
Declaration of consent to the HIV diagnostic test. 
 
 
I ______________________________ declare that I have received pre-test counselling 
and education on HIV/AIDS.  I understand the reasons to be tested and the implications of 
knowing my child’s HIV status.  I am willing to have my child tested to see if he/she is HIV 
positive or negative, and consent to the authorized person taking a sample of blood for 
this purpose. 
 
 
 
 
________________________ 
Parent/Caregiver name 
 
 
________________________ 
Parent/Caregiver signature 
 
 
________________________ 
Date 
 
 
 
 
________________________ 
Researcher name 
 
 
________________________ 
Researcher signature 
 
 
________________________ 
Date 
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Appendix 6: Information packet – child (HIV unknown/HIV negative) 
 
Hello 
 
My name is Anne Zeijlstra.  I work as a doctor here at the Johannesburg Hospital.  I am 
going to help make you sleep for your operation. 
 
Do you know what HIV is?  It is an infection that some children in this country and the 
world have.  This infection can get into the blood of children when they are still in their 
Mommy’s tummies before they are even born.  Sometimes it gets into the blood from 
other blood that has the infection in it.  Remember, HIV can’t get into your blood from 
touching other people or things.  HIV attacks the soldiers of the body so that the body 
can’t fight infection properly.  We can give medicine that helps the body to fight back. 
 
When you fall and hurt yourself, have you noticed that your body stops the bleeding all by 
itself?  This is called blood clotting.  Well, HIV can change the way the body stops 
bleeding. 
 
I want to see how this bleeding is different in children with HIV and children without HIV.  I 
also want to see if the medicine we give for HIV changes the bleeding. 
 
This is where you can help us to understand more about blood clotting.  When you are 
fast asleep for your operation you will get a drip, like all children who have operations.  I 
don’t want you to worry because you will be so fast asleep that you will not feel it at all.  At 
the same time as the drip is put in, I am going to take one-and-a-half teaspoons of blood 
from you so that I can test it to see how it clots; a bit like making a scab to stop bleeding if 
you hurt yourself. 
 
Your treatment will be exactly the same whether you say yes and decide to be a part of 
the study or whether you say no.  You can also decide that you don’t want to be part of 
the study at any time, and nothing bad will happen if you do. 
 
Nobody will know that you have been a part of this study, because I will keep your name a 
secret. 
 
If you agree to be a part of the study, please write your name on the ASSENT FORM, the 
piece of paper that you got with this letter. 
 
Before you write your name on that form, I want you to be sure that you know what I am 
going to do and why I am doing it.  If there is anything that you don’t understand, or if you 
have any questions, please don’t be scared to ask questions at any time. 
 
Thank you. 
 
Anne Zeijlstra 
Anaesthetic Doctor 
90 
 
 
Appendix 7: Information packet – child (HIV positive) 
 
Hello 
 
My name is Anne Zeijlstra.  I work as a doctor here at the Johannesburg Hospital.  I am 
going to help make you sleep for your operation. 
 
When you fall and hurt yourself, have you noticed that your body stops the bleeding all by 
itself?  This is called blood clotting.  I want to see how this bleeding is different in different 
children.   
 
This is where you can help us to understand more about blood clotting.  When you are 
fast asleep for your operation you will get a drip, like all children who have operations.  I 
don’t want you to worry because you will be so fast asleep that you will not feel it at all.  At 
the same time as the drip is put in, I am going to take one-and-a-half teaspoons of blood 
from you so that I can test it to see how it clots; a bit like making a scab to stop bleeding if 
you hurt yourself. 
 
Your treatment will be exactly the same whether you say yes and decide to be a part of 
the study or whether you say no.  You can also decide that you don’t want to be part of 
the study at any time, and nothing bad will happen if you do. 
 
Nobody will know that you have been a part of this study, because I will keep your name a 
secret. 
 
If you agree to be a part of the study, please write your name on the ASSENT FORM, the 
piece of paper that you got with this letter. 
 
Before you write your name on that form, I want you to be sure that you know what I am 
going to do and why I am doing it.  If there is anything that you don’t understand, or if you 
have any questions, please don’t be scared to ask questions at any time. 
 
Thank you. 
 
Anne Zeijlstra 
Anaesthetic Doctor 
Telephone number: 011 488 4397 
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Appendix 8: Assent form 
 
Research Title: Coagulation profiles of HIV-positive and -negative paediatric 
patients undergoing dental extractions at the Johannesburg Hospital.  
 
 
I ______________________________ am happy to participate in this study.  I 
understand that my blood will be taken, for testing, once I am asleep and know 
that this will not hurt me.  I understand what the study is about and my questions 
have been answered.  I know that I can say that I don’t want to be part of this 
study at any time.  I know that nobody will see my name and know that I was part 
of the study when it is finished. 
 
 
 
________________________ 
Subject name 
 
 
________________________ 
Subject signature 
 
 
________________________ 
Date 
 
 
 
________________________ 
Researcher name 
 
 
________________________ 
Researcher signature 
 
 
________________________ 
Date 
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Appendix 9: Data collection sheet 
 
DENTAL EXTRACTION AND 
COAGULOPATHY 
 
Study number 
 
Patient name 
 
Hospital number 
 
 
Age  
Gender  
 
ASA  1  
 2  
3  
4  
5  
 
Co-morbid disease  
  
 
 
 
 
Is the patient HIV positive? Yes  
 No  
 
Platelet count  
CD4 count  
TEG r time  
K time  
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α angle  
MA  
 
 
 
Relevant bleeding >10% blood volume loss  
 Haemodynamic instability  
Admission for bleeding  
Needed blood transfusion  
 
 
 
Surgical complications  
  
 
 
 
 
Anaesthetic complications  
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Anti-viral medication Dose Frequency Route 
Date 
Started 
     
     
     
     
     
     
     
     
     
 
Other  medication Dose Frequency Route 
Date 
Started 
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